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Abstract

FUNCTIONAL AND COGNITIVE STATUS AND MEDICATION COMPLEXITY IN
OLDER ADULTS: THE HEALTH AND RETIREMENT STUDY

By Duaa Bafail, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2018

Major Director: Patricia W. Slattum, Pharm.D., Ph.D.
Associate Professor and Director of Geriatric Pharmacotherapy Program
Department of Pharmacotherapy and Outcomes Science

Introduction: Older adults have high prevalence of chronic illnesses that lead to have complex
medication regimens. They are also more likely to have cognitive and functional impairments.
Both cognitive/functional impairments and medication regimen complexity increase the risk of
medication non-adherence. The objective of this study is to evaluate the association between
prescription medication regimen complexity and cognitive/functional status at baseline and after
two years, and to assess how changes in cognitive/functional status are associated with changes
in medication regimen complexity.
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Methods: This study used nationally representative sample of community-dwelling older adults
from the Health and Retirement Study, followed over a two-year period. The exposures
examined were cognitive status, and two types of functional status (Activities of Daily Living
(ADLs) and Instrumental Activities of Daily Living (IADLs). The association between
cognitive/functional status and medication regimen complexity was examined at baseline and
after two years. Similar models were used to examine the relationship between
cognitive/functional impairment and sub-components of complexity, and to assess how changes
in cognitive/functional impairment were associated with changes in medication complexity over
two years.
Results: Impairment in ADLs were associated with higher medication complexity at baseline
(p=0.0029) and after two years (p=0.0243). Impairments in IADLs were associated with higher
regimen complexity at baseline only (p=0.0130). Stratifying by depression status, IADL
impairment was found to predict higher complexity at both time points, but only in participants
without depression. Cognitive impairment was associated with lower medication regimen
complexity at baseline (p<0.0001) and after two years (p=0.0392). Changes in
cognitive/functional status were not associated with change in medication complexity over two
years.
Conclusion: ADL impairment was strongly associated with higher medication complexity.
IADL impairment showed some association with higher medication complexity, but this
relationship may vary according to depression status and requires further investigation.
Recognition of these impairments may offer health care providers the opportunity to intervene by
re-assessing medication regimens for patients with functional impairments. Cognitive
impairment was associated with lower medication complexity. Changes in cognitive or
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functional were not associated with changes in complexity. Further study is needed to investigate
this relationship over a longer period of time.

xv

Chapter 1: Introduction

1.1 Introduction
Complex systems are prone to error, and where complexity exists the large number of
interconnected elements increases the opportunity for errors to occur and that applies to
medication regimens.1,2 With increases in the availability of prescription and non-prescription
medication, medication regimen burden for patients has grown.2 Clinicians provide their care to
the patient that has multiple comorbidities at a time when the development and the availability of
medications has increased, which further complicates the medication regimen making complex
medication regimens inevitable.3
With increases in life expectancy and a growing range of medications available to treat
chronic conditions, the use of prescription medications is likely to continue to increase as well,4
particularly for community-dwelling older patients. These individuals constitute the largest
group of consumers of prescription medication in the US, with approximately 20% taking ten or
more prescription medications.5,6 Current medical practice is largely based on guidelines, which
help healthcare providers prescribe the right treatment for each condition. Although the use of
guidelines helps reduce the risk of non-evidence-based prescribing, this increases the chances of
putting patients with multiple conditions on a large number of medications chronically. Patients
with multiple chronic diseases such as diabetes, hypertension, chronic obstructive pulmonary
disease and depression are likely to be on several medications7,8 which is referred to as
polypharmacy.9 The median number of medications prescribed to people aged 65 years or older
doubled from 2 to 4 between 1988 and 2010. The proportion of older adults taking five or more
medications has nearly tripled from 12.8% in 1988 to 39.0% in 2010.10
1

The increased use of medications is likely attributable to the concurrent increase in ageassociated chronic conditions.11 The estimated prevalence of having 2 or more
chronic conditions is 64% among adults aged 65 to 74 years and 71% among those aged 75 years
or older.12 The prevalence of functional impairment and cognitive impairment also increases
with age.13 The aging process generally results in changes and reductions in functional ability,
such as declines in physical fitness, flexibility, strength, endurance, and agility, resulting in
difficulties preforming normal daily activities.14,15 As a result, the ability to function
independently often declines with age.
Age also plays a role in accelerating the development of neuronal dysfunction, neuronal
loss, and cognitive decline, which contributes to multiple problems like decreased intellectual
function and neurodegenerative diseases.16 In addition to age, older adults are often more likely
to suffer from conditions such as heart disease, stroke, and arthritis that can lead to functional
and/or cognitive decline.17,18,19 This is particularly concerning in light of the fact that functional
and cognitive impairment are risk factors for difficulty adhering to a prescription medication
regimen. Reductions in mobility may create difficulties in filling prescriptions; decline in
functional ability to manipulate small objects may lead to difficulties opening prescription
containers. These functional impairments can act as barriers to compliance with a prescription
medication regimen.20,21 Furthermore, reduction in the ability to remember the details of the
medication regimen can also contribute to non-adherence.22 Adherence to a therapeutic plan is
vital for patients in order to get maximum benefits in the form of disease control and health
maintenance. This is more important in the older adult population in which a large proportion
living with chronic diseases resulting in polypharmacy. Poor adherence to medicines has
negative effects on the individual. On a personal level, it results in delayed resolution of
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illnesses, the worsening of the symptoms of the disease and can lead to an increase in healthcare
costs. In United States, nonadherence is estimated to cost billions of dollars annually.23,24
Not taking medications at the correct time, missing doses, or not following other
medication-related instructions could potentially result in the patient receiving a suboptimal
clinical outcome and therefore lead to therapeutic failure.25 Poor patient compliance with
medication regimens has been estimated to cause about 10% of hospital admissions in the United
States.26 The World Health Organization (WHO) suggests that greater health benefits could be
achieved by improving patient compliance with existing treatment regimens than by developing
new medical treatments.27 Medication regimen complexity has been associated in previous
studies with poor adherence to treatment, and was also identified by the WHO as one of the
factors affecting adherence.25,28 Several studies have also shown that simplification of
medication regimens can reduce non-adherence.25,29,30 Large numbers of medications,
complicated medication schedules, or special instructions/requirements (such as cutting or
breaking tablets or food interactions) can all contribute to medication regimen complexity and
make it more difficult for patients to comply with the treatment plan.31,32 Complexity is one of
the primary causes of patients’ non-adherence, with complex medication regimens reducing the
likelihood of adherence to treatment.31 Therefore simplifications of medication regimens and
greater attention to managing complexity are potential remediation strategies for poor adherence,
and will be critical in helping patients to use their medications correctly.33
1.2 Statement of the Problem
Although medication regimen complexity and cognitive/functional impairments have
both been associated with poor medication adherence, there is limited data on the relationship
between cognitive/functional impairments and medication regimen complexity. One study by
Herson et al. (2015) showed that independence in activities of daily living was inversely
3

associated with high regimen complexity.34 Study by Wimmer et al. (2015) showed no
significant association between high medication regimen complexity and ADLs. In this study
and a study by Lee et al. (2012), the association between medication complexity and cognitive
impairment was evaluated, and the results showed medication regimen complexity was lower in
participants with cognitive impairment.35,36
Further study of this relationship is needed, particularly in the United States population, as most
of the existing studies were conducted in a non-United States population, which may have
limited the generalizability. Furthermore, all existing studies were cross-sectional; there is a need
for longitudinal studies, which may contribute new information to the understanding of this
relationship. The proposed study will be the first to use a nationally representative sample of the
United States older adult population to assess the relationship between medication regimen
complexity and cognitive/functional impairments using a longitudinal design.
1.3 Research Questions and Hypotheses
Research Question: Is there an association between the functional/cognitive status and
medication regimen complexity among older adults living in community, both cross-sectionally
and over time?
Hypotheses: The hypotheses of this study are as follows:
H1A: There is an association between cognitive status and medication regimen complexity
among older adults.
H0A: There is no association between cognitive status and medication regimen complexity
among older adults.
H1B: There is an association between functional status and medication regimen complexity
among older adults.
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H0B: There is no association between functional status and medication regimen complexity
among older adults.
1.4 Study Objectives
The objectives of this study are as follows:
I.

To characterize medication regimen complexity among community dwelling older adults
in the United States

II.

To assess the association between medication regimen complexity and cognitive status
1. Evaluate the association between medication regimen complexity and cognitive
status at baseline
2. Evaluate the association between medication regimen complexity and cognitive
status after two years
3. Compare factors that contribute to medication regimen complexity in participants
with and without cognitive impairment.
4. Assess the change in medication regimen complexity score and its association
with change in cognitive status over two years

III.

Assess the association between medication regimen complexity and functional status
1. Evaluate the association between medication regimen complexity and functional
status at baseline
2. Evaluate the association between medication regimen complexity and functional
status after two years
3. Compare factors that contribute to medication regimen complexity in participants
with and without functional impairment.
4. Assess the change in medication regimen complexity score and its association
with change in functional status over two years.
5

1.5 Significance of the Study
This study contributes to understanding the relationship between cognitive/functional
impairment and medication regimen complexity in a nationally representative population of
older adults. Older adults, who make up a significant percent of the US population, are more
susceptible to the negative outcomes of medication use due to the higher chronic disease burden
found in this population. This is the first study that will evaluate the association between
cognitive/functional impairment and medication regimen complexity in nationally representative
population of older adults living in the community in 2004 and 2006 and the change of
medication regimen complexity over two years period. More importantly, the associated
cognitive and functional decline in this age group also increases the risk of harm from complex
medication regimens. This makes it particularly important to examine these populations. This
study could assist healthcare providers in identifying older adult’s patients who may require
cognitive and functional assessments and assessment of medication complexity prior to therapy
initiation. These assessments ensure that medication regimes are tailored to individual patients.
In addition, this study will attempt to highlight the importance of cognitive and functional
assessments in clinical settings in order to identify individuals who are at risk of poor adherence.
This can help to prioritize older adult’s patients who need medication reviews and revision of
their treatment plan to maintain adherence, which will help them to achieve maximal health
benefits. Furthermore, the results will help efforts to maximize medication adherence by
increasing healthcare providers’ awareness of the need to minimize the complexity of medication
regimens.

6

Chapter 2: Background and Literature Review

The purpose of this study was to examine the association of cognitive and functional
status with medication regimen complexity in older adults living in the community. This section
will provide background information on the definition of medication regimen complexity, the
definition and prevalence of cognitive impairment in older adults, the definition and prevalence
of functional impairment in older adults, multiple medication use and medication regimen
complexity in older adults, cognitive impairment and adherence in older adults, functional
impairment and adherence in older adults, medication regimen complexity, adherence, and other
clinical outcomes in older adults and a literature review of the evidence relevant to this research
study, namely, literature regarding the association of cognitive or functional impairment and
medication regimen complexity in older adults.
2.1 Definition of Medication Regimen Complexity
Medication regimen complexity has been a subject of study for decades,37 however the
exact parameters of what constitutes complexity and how to measure these parameters has led to
differing definitions of this construct throughout the literature. With increasing use of multiple
medications, the impact of complexity is just beginning to be appreciated by researchers. The
idea of polypharmacy, which is based on the number of medications an individual is taking, is
not enough on its own to explain the large discrepancies seen with adverse drug events or
adverse outcomes. It is also not sufficient for the evaluation of the impact of regimens on
outcomes in intervention studies.38 Additionally; there is a sense amongst clinical providers that
the concept of polypharmacy may not fully explain observed results for adverse drug events and
7

subsequent adverse outcomes. Medication regimen complexity, unlike polypharmacy, provides
detailed and nuanced data for researchers and practitioners.38 Early studies defined medication
regimen complexity as dose multiplied by the frequency of administration.37 Other studies
considered medication complexity solely as the number of medications or the number of tablets
taken per day. Other researchers went further to account for complexity by combining the
number of doses per day, in addition to the number of medications taken, to make up the
components of medication complexity.39–41 Another study evaluated the complexity of
medications by multiplying the number of medicines administered by frequency of
administration.42
Previously, the term ‘regimen complexity’ has been used interchangeably with
‘medication count’ in a manner similar to the concept of polypharmacy. This did not take into
account other facets of complexity such as different dosage forms and dosing frequencies.3,43
However, a patient’s compliance is influenced not just by the number of medications taken but
also by other factors, which make up regimen complexity. These include the number of doses to
be taken, the route of administration, the preparation steps prior to administration and variable
administration schedules.37 To examine these factors, the Medication Complexity Index was
developed by a graduate student (Kelly, 1988) to evaluate medication regimen complexity.44
However, limitations in the original design made it quite difficult for users to record information.
Due to these difficulties, George et al. (2004) redesigned the Medication Complexity Index and
developed a 65-item medication regimen complexity index (MRCI) tool as a way to quantify
several components of medication regimen complexity. This redesigned instrument, accounts for
the dosage form (e.g. tablet, inhalation), dosing frequency (e.g. once a day, three time a day), and
additional directions (such as crush the tablet, or take with food). Other information taken into
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account in this tool includes multiple unit dosing (2 tablets, 2 puffs) and specific timing (e.g. at
3pm).38 Weights were assigned to dosage forms, frequency of doses, and additional directions.
Although number of medications is one contributing factor to the MRCI score, the
definition of MRCI is different than the definition of polypharmacy38 because it also includes
other aspects of the medication regimen.39 The MRCI is a widely used instrument in studies and
has been validated in a study by George et al. on chronic obstructive pulmonary disease patients.
To measure that prescription medication associated with that disease; the tool was validated by
an expert panel who subjectively ranked six regimens to ascertain the criterion validity. This
indicated strong agreement (Kendall’s W = .8, p = 0.001). The inter-rater and test-retest
reliabilities for the total score and scores from the individual sections of the MRCI as ≥0.9 38.
Further validation was done by Libby et al. included not only prescription medications
associated with the disease but also over the counter (OTC) medications and other prescription
medications which are often referred to as patient-level MRCI (pMRCI).32’45 The patient-level
MRCI has been used to measure medication complexity in several patient populations including
depressed geriatric patients, organ transplant patients, patients with heart failure, HIV patients,
hypertensive patients, patients with diabetes, and patients on dialysis.46–51 Table 2.1 below shows
examples of some MRCI components and their weighted scores. The full MRCI is included in
Appendix A.

9

Table 2. 1 Medication regimen complexity index components and scoring
Component category

Elements

Elements score

Dosage form

Once daily
Three times daily
Hour intervals (e.g. Q12 h)

Dosing frequency

Oral (e.g. tablet)
Topical (e.g. creams, ointments)
Eye drops

1
2
3

Additional direction

Break or crush table
Take at specific time (e.g. in the morning)
Relation to food (e.g. take with food)

1
1
1

1
3
2.5

Note: This table contains a subset of MRCI elements for demonstration purposes, the full MRCI can be
found in Appendix A

2.2 Definition and Prevalence of Cognitive Impairment
The prevalence of cognitive impairment increases with age.52 Its effects impact families,
carers, and health and social care providers as well as the patient.53 Cognitive impairment is
defined as a state where a person has trouble learning new information, remembering things, and
concentrating or making decisions which can affect them to function adequately and
independently in everyday life.54 Cognitive impairment can range from mild to severe.54
Mild cognitive impairment (MCI) is a transitional stage which falls between normal
ageing and dementia, and is defined as “an overall mild decline across cognitive abilities that is
greater than would be expected for an individual’s age or education, but is insufficient to
interfere with social and occupational functioning, as is required for a dementia syndrome.”55
Patients with mild, cognitive impairment often complain of memory loss but show no evidence
of dementia. Individuals may start to notice some minor changes in their cognitive function,
including a decline in cognitive abilities such as thinking skills and memory.52 These progressive
changes are usually noticeable by the patients experiencing them or by other people around them
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like a family member, however these changes do not significantly affect their functioning and the
patients are still able to carry out their activities of everyday living.54
In severe cognitive impairment, the patient loses the ability to understand the meaning of
or to remember the importance of things and loses the ability to talk or write. The loss of such
basic but important functions results in an inability to live independently.56,57 The underlying
causes of mild cognitive impairment are not well understood however, there are some risk
factors that are most strongly linked to mild cognitive impairment that are the same as those for
dementia, which include a family history of the disease, progressing age, and chronic diseases
such as cardiovascular disease in which blood vessels, including those that support brain
function, experience reductions in blood flow.58
The prevalence of mild cognitive impairment is between 3% and 19% in the older adult
population, with an incidence of 8 to 58 cases per 1000 individuals per year.59 Cognitive
impairment is associated with a higher risk for progression to dementia. The progression rates
are estimated at 10% to 15% per year amongst older individuals with cognitive impairment
compared to 1% to 2.5% among cognitively healthy older adults.27 A recent study done by
Plassman et al. used data from the “Aging, Demographics and Memory Study (ADAMS study)”
to estimate the incidence of CIND (Cognitive Impairment with no Dementia) and the progression
of CIND to dementia during the follow-up period. The ADAMS study used a longitudinal
design, and included individuals from all the regions of the US.62 The study reported that an
estimated 5.4 million older adults (22.2% of the United States older adult population) had
cognitive impairment without dementia. At follow-up, 11.7% of those with cognitive impairment
had progressed to dementia.62 A range of diagnostic and screening tests are available to assess
cognitive function. Some are more detailed than others, and different tests assess different
cognition domains. The Health and Retirement Study used the Telephone Interview for
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Cognitive Status (TICS). The TICS is a screening tool not intended for diagnostic purposes, and
omits certain areas examined by other tests, such as visuospatial and executive function.
Domains assessed by the TICS include orientation, attention, short-term memory, sentence
repetition, immediate recall, word opposites, and praxis.63
2.3 Definition and Prevalence of Functional Impairment
Functional status is “an individual's ability to perform normal daily activities required to
meet basic needs, and maintain health and well-being without support.”64,65 Functional ability is
central to overall independence and is a key determinant of quality of life.66 Difficulties that
substantially interfere with or limit role functioning in one or more major life activities is
referred to as functional impairment.66 Individuals with functional impairment often need the
assistance of another person to perform one or more daily activities.66 Functional impairment is
assessed by many tools which could be self-reported or caregiver reported and characterized by
being unable to carry out activities of daily living, which can be assessed using the activities of
daily living tool (ADLs) that assesses tasks such as getting out of bed, dressing oneself and
performing personal hygiene. Instrumental activities of daily living (IADLs) tool assesses tasks
such as eating, walking, shopping, housekeeping and preparing meals.66,64
ADLs are the primary and fundamental elements of self-care. The inability to
independently perform even one of these activities may signal the need for supportive services.
IADLs are typically higher-level activities people must perform in order to remain independent
in the community and are often a basis for assessment of needs for services to assist in
maintaining independence.66,67 The decline of functional status in older adults can lead to an
inability to live independently at home and predisposes them to social isolation. This decline can
be accelerated by personal risk factors which vary from patient to patient and can lead to a rapid
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decline in functional status, or can be slowed by the introduction of external support and the
application of appropriate interventions.68,69
Health promotion and halting functional decline in older adults is a longstanding public
health policy issue in the United States.70 However, there is no general consensus regarding
changes in the trajectory of late-life functional status and disability in the older adult population
over time. Some argue that late-life functional status and disability for older Americans has
never been better, while others argue that the situation has not been improving 71,72 With the
general population getting older, there has been a proportional rise in the decline of functional
ability.17 There has also been a concurrent rise in the prevalence chronic illnesses, which increase
the risk of a decline in functional status.
The presence of multiple illnesses often reduces the ability to compensate as one would
with a diagnosis of a single illness. As a result of this, comorbidities in older adult patients may
lead to greater disability than generally anticipated.17 Chronic disease includes conditions such as
diabetes, cardiac disease, neurological conditions, cancer, obesity, and dementia. Some of these
conditions are rare but very highly disabling like stroke, while other conditions such as arthritis
are more common but may be less disabling.73 The disabling effect can vary depending on the
task the patient is trying to perform. For example, heart disease is more likely to produce
difficulty with tasks involving physical activity such as housework, while neurological
conditions such as Parkinson’s disease may interfere with tasks requiring fine motor control.74
Both the impairment and the underlying health condition should be addressed in older adults so
that interventions can be developed to reduce the level of disability.
The coexistence of two or more health conditions (comorbidity) can result in more
disability. As the number of impairments increases from one to four, the percentage of persons
reporting dependence on others for assistance with activities increases exponentially (7%, 14%,
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28%, and 60% respectively).75 A recent study assessing functional status among individuals 65
and older participating in Medicare managed care plans collected data longitudinally from 19932007. The results of this study showed declines on all measures of function status (ADLs and
IADLs). After an average of 8 years of follow-up, 36.6% of participants showed at least two new
ADL limitations, 32.3% developed at least two new IADLs limitations.76 Among older adults
admitted to medical hospital units, the prevalence of pre-admission ADL disability was 20.7%
among those 60-69 years, and 41.2% for those aged 70 or older. The prevalence of pre-admission
IADL disability was 29.6% among those 60-69 years and 62.9% among those aged 70 years and
older.77
2.4 Multiple Medications Use and Medication Regimen Complexity in Older Adults
It has been well-documented that older adults in the United States are likely to be taking
multiple medications concurrently.78,79 With medical advancements and public health
improvements resulting in increased life expectancy, there are increasing numbers of older adults
with multiple chronic conditions who require several medications to manage their conditions.80,81
Older adults with multiple comorbidities are also more likely to experience cognitive and
functional impairments.82 13% of older adults who have one or more chronic conditions also
experience functional impairment and over 26% of older adults who have five or more chronic
disease have functional impairment.82 Chronic conditions are also associated with cognitive
impairment, with approximately 24% of all cases of cognitive impairment without dementia are
attributable to chronic medical illness.62 Because cognitive and functional impairments are
associated with chronic disease, it is not surprising that these individuals are more likely to use
multiple medications, and more likely to be at risk for medication-related problems.81,83
The use of multiple medications can easily result from following clinical practice
guidelines for a small number of chronic conditions such as hypertension, osteoarthritis, chronic
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obstructive pulmonary disease and diabetes.84,7 Multiple medications obtained from multiple
prescribers and pharmacies, and the use of over-the-counter medications and alternative therapies
such as herbal medicines contribute to medication-related problems.85 Along with the widespread
use of multiple drugs, older adults are frequently prescribed medication therapy with varying
doses, different frequencies and varying routes of administration,84 as well as various dosage
forms such as tablets, inhalers or injections.86,87 A sample of older adults aged 65 years and older
with a diagnosis of depression was randomly selected in ambulatory clinics at the University of
Colorado and University of San Diego. The results of this study showed that the complexity
score for individual were on average 17.62 (San Diego) and 19.36 (Colorado). Dosing frequency
contributed to 57-58% of the MRCI score, with patients having an average of 7-8 unique dosing
frequencies in their regimens. For additional directions attached to a patient medication (e.g.
crush pill, take with food, taper dose),at both sites, there was an average of 3 additional
directions per regimen to clarify dosing.46 The increased use of medications is likely attributable
to the concurrent increase in age-associated chronic conditions. A study by Libbyet al. (2013)
showed that using patient-level MRCI scores which included prescription drugs and over the
counter medications across four chronic diseases, found that MRCI was higher in the geriatric
depression cohort when compared to other cohorts for other diseases. The next highest
complexity was the diabetes cohort followed by the HIV cohort and the hypertension cohort.
Across all cohorts, most older adults were using dosage forms other than tablet/capsule. Large
numbers of participants also had at least three additional directions and at least three different
dosing frequencies.32 As a result, the complexity of medication regimens increases making it
more difficult for patients to comply with their planned treatments.38 Medication regimen
complexity increases the difficulty of self-care in the home for older adults.
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Although many factors in medication regimen complexity may contribute to how
complicated a medication regimen is, each element of complexity may differ in the extent to
which it contributes to total complexity and complicates the medication regimen. A study by
Advinha et al. (2014) used the MRCI to assess medication regimen complexity in
institutionalized older adults, and found that the factor with the greatest contribution to
complexity was number of medications.88 Another study conducted by Wimmer et al. (2015)
also showed that the number of medications was highly correlated with MRCI.36 In the Advinha
study, when they compared regimens with the same number of medications, dosing frequency
was most closely associated complexity (r=0.922), followed by dosage form (r=0.768) and then
additional directions (r=0.742).88 A study by Elliott et al. (2011) also found that the most
common regimen simplification implemented by hospitals was reduction in dosage frequency,
which also led to reduction in the MRCI.89 Finally, a study by Libby et al. showed that among all
contributing factors to patient-level MRCI scores, dosing frequency contributed the most
complexity points to the MRCI score (55%–64%), followed by dosage form.32 Regardless of
which component contributes the most to complexity, complexity itself is associated with
detrimental outcomes for patients.89 Complex medication regimens can lead to clinical
consequences from both medication over- and under-use, and as the complexity increases, the
risk of administration error also increases. Patients with complex medication regimens are less
likely to fully comply with therapy compared to patients with simpler treatment regiomens.33
2.5 Cognitive Impairment and Adherence in Older Adults
Poor medication adherence is very common and is a major risk factor for health
problems. This issue disproportionately affects older adults, as they are the highest users of
prescription medications.90,91 Adherence can be defined as taking the correct amount of a
medication at the right time while following the instructions given with the medication, such as
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taking it with or without food.92 Older adults are at a higher risk of suffering the negative effects
of non-adherence with therapy, particularly due to the high prevalence of chronic comorbidities
in this group.83 Management of chronic conditions often requires complex medication regimens,
which is a known risk factor for poor adherence in older adults.29,93
Self-management and the ability to perform self-care helps maintain patient
independence and empowers the patient to achieve effective disease management. Age-related
reductions in the function and mobility put older patients at a higher risk of non-adherence than
younger patients. Declines in cognitive ability further compound the problem and can worsen
adherence.21 Cognitive processes are required in order to manage a medication regimen on a
daily basis. As a result, older adults with cognitive impairment are less likely to succeed in
following complex medication regimens as intended by the prescriber.94 Cognitive impairment is
among the most important risk factors for medication non-adherence in older adults. Nonadherence is estimated to be almost three times higher in patients with cognitive impairment.95
Cognitive impairment has also been shown to double the risk of non-adherence among older
adults patients using antihypertensive medications.96 Patients with cognitive impairment often
have trouble understanding and following treatment recommendations. Such individuals may
forget doses or take a dose multiple times leading to inadvertent overuse. This is often related to
impairment of higher-level cognitive functions such as executive function, which is essential for
planning and monitoring medication use.92,94 Even individuals who retain the ability to perform
basic tasks related to adherence, such as reading and being able to tell time, may be unable to
comply with a complex regimen if elements of executive function such as planning and retaining
information are impaired.97
Adherence to a medication regimen requires understanding the dosing directions and
schedule, which requires planning to be able to take the drug at a specific time or under specific
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circumstances such as after a meal. The ability to recall instructions for responding to missed
doses and follow through with related plans is also required.98 Deficits in executive function
lead to impairments in the ability to create plans and to organize and carry out tasks. These are
key skills involved in managing complex medication regimens, and as a result executive function
deficits impair adherence to therapy.98 This can result in poor disease control, medication errors,
increased risk of hospital admission, and loss of independence in the area of medicine
management.99,100 Thus assessment of executive function and cognitive impairment will be
critical to identifying older adults patients at risk for therapeutic failure due to poor adherence.92
2.6 Functional Impairment and Adherence in Older Adults
Age related and disease related changes are common among older adults and they often
experience decreases in functional ability and greater difficulty in performing everyday tasks 101
It is associated with a lower quality of life, a higher risk of health decline and contributes to
health care costs.102 Functional decline can occur as a result of several factors including
cognitive impairment, as it has long been part of the diagnostic criteria for cognitive impairment.
A study by Farias et al. (2006) examined different types of cognitive impairment and their
relationship with functional ability. This study found that compared to controls without cognitive
impairment, individuals with mild cognitive impairment experienced more functional limitations,
and individuals with dementia experienced an even higher level of functional impairment.103
Individuals with such impairments often experience difficulty in adhering to medications due to
these impairments.104
Functional impairment can also result from other causes such as chronic disease that can
result in reduced mobility and poor manual dexterity, leading to reduction in functional ability.
When these abilities are necessary for taking medication, this can result in reduced adherence.105
Medication adherence was examined among Medicare patients with heart failure. Individuals
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experiencing functional impairments were found to have lower levels of adherence over a oneyear period.106 Another study compared antihypertensive medication adherence in patients with
and without functional impairment using medical claims data of the National Health Insurance
(NHI). This study also found that adherence was lower in individuals with functional
disabilities.107 A recent study examined the impact of impaired mobility on medication
adherence in older adults. According to this study, patients with severe or moderate mobility
impairment had lower adherence rates to medication (62% and 66% respectively) than
individuals with no mobility impairment (73%).108 Reduction in functional ability often makes it
difficult for patients to manage their medications and leads to considerable difficulties with tasks
such as opening child-proof containers. Several medication types such as nebulizers, inhalers and
eye drops require physical manipulation in order to administer them correctly. Conditions which
impair joint function or manual dexterity may make the use of these medications difficult.109 Due
to these limitations, individuals with functional impairment are often at greater risk of
medication non-adherence.110,111
2.7 Medication Complexity, Adherence, and Other Clinical Outcomes in Older Adults
Previous research has shown a correlation between negative clinical outcomes in older
adults and complex medication regimens. Medication regimen complexity is reported to be
associated with self-administration errors.40 Family caregiver medication administration
problems were also found to increase with medication regimen complexity, leading to the
suggestion that complex medication regimens of individual patients could be used to identify
caregivers at risk of experiencing difficulties administering medication.112 Medication regimen
complexity is also associated with higher rates of hospitalization, 113’114 and increases in MRCI
score increased the probability of adverse drug events (ADE).113 Higher MRCI scores were
associated with an increase in all-cause mortality.115 Complex medication regimens may be
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particularly detrimental to patients who have experienced hospitalization. More complex
medication regimens have been shown to be inversely associated with the probability of
discharge directly to home from hospital.116 In addition, complex medication regimens also have
an impact on patient knowledge of new medications added to their regimens. Newly prescribed
medications are common, with an estimated 40% of patients discharged from the emergency
department receiving at least one new medication. In patients with already complex regimens,
the addition of another medication to an already complicated list can make it more difficult to be
knowledgeable about their medications.117
Poor adherence to therapy has been shown to have a negative effect on patients and to
result in higher medical costs.23 The relationship between medication regimen complexity and
adherence has been examined in previous studies, demonstrating that high MRCI negatively
impacts adherence in older adults.118’119 The aim of treatment with medication is to optimize the
benefit from medication while minimizing side effects. Unfortunately, this balancing act often
requires detailed directions, which make treatment plans more complicated. Older adults
generally have more difficulty adhering to complex treatment plans.93 Both overall complexity
and specific components of complexity can interfere with adherence.25 Number of medications is
negatively associated with adherence that is, the presence of more medications was associated
with worse adherence.120 Also having simple or complex dosing schedules would affect
adherence as adherence to therapy is lower with more complex dosing schedules, and this has a
negative impact for patients.121 A retrospective cohort study investigated adherence in patients
with type 2 diabetes taking oral anti-diabetic medications, and reported that complex treatment
plans with more frequent dosing schedules were linked with poor adherence to therapy.122
Patients on twice-a-day treatment plans had lower adherence over time than those on once daily
dosing regimens.123 Having the patient on lower dosing frequency is better and recommended for
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improved adherence.124 Other elements of complexity such as drug instruction and the dosage
form can also impact adherence. Less complicated regimens with fewer doses and little or no
special instructions (such as food and storage requirements) were associated with better
adherence. 125 Multiple dosage forms reduced the adherence rate to treatment regimens with
multiple components such as systemic corticosteroids and inhaled and long-acting
bronchodilators in patients with severe asthma.126 These factors all play a part in influencing
patient adherence to treatment, and are therefore are important considerations in promoting good
adherence to medication therapy.
2.8 Association of Cognitive/Functional Impairment and Medication Complexity in Older
Adults
Introduction
The population of the United States is aging rapidly. By 2050, the population aged 65 and
over is projected to be 83.7 million, almost double the number of older adults that there were in
2012.10 Older adults also are the largest consumers of medication in the US, largely due to an
age-associated increase in chronic conditions.1 The management of these chronic conditions
often requires the use of multiple medications for a prolonged period of time.79 Because of this,
multiple medication use is a common aspect of providing health care to older adults, leading to
increase in prescribed medication use by older adults2. In addition, older adults are often
prescribed medications with multiple dosing schedules, multiple dosage forms such as tablets
and inhalers, and multiple routes of administration, all of which lead to complex treatment
plans.127 Higher medication regimen complexity increases the risk of poor adherence.118’119 Older
adults are also at risk for decline in their cognitive and functional abilities,13 which can act as
barriers to compliance with a prescription medication regimen.20 It is therefore important to
understand the association of cognitive and functional impairment with medication regimen
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complexity in older adults. The objectives of this literature review are to identify and synthesize
information from studies of cognitive or functional impairment and medication regimen
complexity in older adults, to determine the factors associated with medication regimen
complexity in older adults, and to identify gaps in the literature that should be examined.
Methods
The literature search was conducted from January 1998 to January 2018 in
PUBMED/CINAHL and Google Scholar. In PUBMED and CINAHL, the search used the terms
“poly-pharmacy” OR” medication” OR “medicine” OR “pills burden” AND “treatment
complexity” OR “regimen complexity” OR “medication regimen complexity” AND “cognitive
status” OR “cognitive impairment” OR “cognitive decline” AND “functional status” OR
“functional impairment “OR “functional decline”. In Google Scholar, targeted searches using
individual terms or combinations of terms were used to find additional articles. Title and
abstracts were first screened for inclusion and exclusion criteria, and duplicates were removed.
Full-text articles were then screened for eligibility. Inclusion criteria included: (1) a study
population consisting of older adults aged 60 years or older; (2) Observational studies or
intervention-based studies; (3) cross sectional or longitudinal studies; (4) was conducted in or out
the United States; and (5) the assessment of cognitive or functional impairment in the study
population. Exclusion criteria included: (1) not using a validated tool to assess complexity of
medication regimen; and (2) journal articles not written in English. The search over all databases
yielded 225 results. In addition, the citations included in review articles were searched for
relevant literature that was not captured in the literature search. After applying the inclusion and
exclusion criteria at the title, abstract, and full-text screening stages, a total of three original
research articles were found. The flow of articles throughout these stages is contained in Figure
2.1 Articles are summarized in Table 2.2
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Studies identified through
sources searching
(n=225)
Records after duplicates removed
(n=68)
Abstracts were included
for further analysis
(n=157)
Articles did not meet the inclusion
criteria, such as intervention or
observational studies not examining
the associations of interest (n=129)
Full-text articles assessed
For eligibility
(n=28)

Articles that were not dealing with the
association between cognitive or
functional impairment and medication
complexity (n=25)

Articles based on older adults and looking at the association
between cognitive/functional impairment and mediation
regimen complexity or the factors associated with medication
regimen complexity in older adults (n=3)

Figure 2.1 The Flow of Articles Throughout the Stages of Literature Review
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Table 2. 2 Summary of Literature Assessing the Relationship Between Cognitive/Functional
Impairment and Medication Complexity Among Older Adults
Study

(Herson et al. 2015)34

(Wimmer et al. 2015)36

(Lee et al. 2012)35

Country

Australia

Sweden

USA

Setting and sample
size
People aged 65 years
and older living in
LTCFs (n= 383)

People aged 60 years
and older in
community
and in residential
aged care, living in
Central Stockholm
(n=3348)

Assessment

Finding

To investigate factors Independence in activities
associated with
of daily living (ADLs) and
medication regimen
dementia were associated
complexity in older
with lower regimen
resident living in LTCFs
complexity.

To investigate factors
associated with
medication regimen
complexity in older
people

Medication regimen
complexity was lower in
participants with cognitive
impairment. No significant
association was found
between (ADLs) and
regimen complexity.

US. Older population To evaluate whether
Medication regimen
aged 70- to 79-years, cognitive impairment is complexity for prescription
(n=3075)
associated with
and OTC medications was
medication complexity lower in participants with
for prescription and
cognitive impairment
over-the-counter (OTC)
medications
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Results: Summary of Studies
Two studies assessed the association between cognitive impairment and medication
regimen complexity in two different settings. One study assessed dementia and its association to
medication regimen complexity. The study by Lee et al. (2012) found that cognitive impairment
was associated with lower prescription complexity after adjusting for other health status,
demographics, and access to health care (RR 0.89; 95% CI 0.80 to 0.99). The number of
prescription medications was not significantly different between cognitively impaired and
cognitively intact individuals. Therefore, the lowering in the prescription medication complexity
was not due to lowering in the prescription usage but rather due to less complex dosage from,
and less dosage. Interactions between cognitive impairment and each chronic condition were
assessed and did not produce statistically significant results. Cognitive impairment was also
associated with lower over the counter (OTC) medication complexity (RR 0.76; 95% CI 0.64 to
0.93). The number of the (OTC) medications was also lower for those with cognitive impairment
(RR 0.76; 95% CI 0.66 to 0.88). Thus, the decreased OTC complexity likely reflects a decreased
number of OTC medications, rather than a difference in other components of complexity.35
The study by Wimmer et al. (2015) found that among older adults, predictors of being in
the highest MRCI quintile were older age (OR=1.04, 95%CI 1.02;1.05), not living at home
(OR=0.35, 95 % CI 0.15;0.86), greater chronic disease (OR=2.17, 95 % CI 1.89;2.49), good
cognitive performance (OR=1.06, 95%CI 1.01;1.11), self-reported pain during the last 4 weeks
(OR=2.85, 95%CI 2.16;3.76), and receiving help in sorting medications (OR=4.43 95 % CI
2.39;8.56) in comparing to those in lowest quintile. This study did not find a significant
association between ADL score and medication regimen complexity score (OR=1.15, 95%CI
0.88; 1.52).36 The study by Herson et al. (2015) assessed the association between several chronic
diseases and medication regimen complexity. This study found that diseases associated with
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higher complexity included diabetes, heart failure and pulmonary disease. This study also
evaluated functional ability using activities of daily living (ADLs) and dementia, found that ADL
and dementia were inversely associated with high regimen complexity (OR: 0.72, 95% CI: 0.62–
0.84), (OR: 0.34, 95% CI: 0.17–0.67) resprectivey.34
Discussion
This review was conducted to understand and summarize the current literature on the
association between cognitive/functional impairment and medication regimen complexity among
older adults. The search yielded three studies, out of which two were focused on the factors
associated with medication regimen complexity in older adults and one study assessed the
association between cognitive impairment and medication regimen complexity in older adults.
Lee at al. (2012) evaluated whether cognitive impairment was related to medication
regimen complexity for both prescription and over-the-counter (OTC) drugs. They found that
cognitive impairment was associated with lower prescription complexity and lower OTC
complexity. The authors suggested that prescribers may have simplified medication regimens to
make the medication management easier for people with cognitive impairment. They also tested
the difference in number of prescriptions and OTC medications between those with and without
cognitive impairment and found that only OTC medication was significantly lower in those with
cognitive impairment, and number of prescription medications was non-significantly lower. They
attributed most of the reduction in prescription medication complexity to lower complexity from
form and dosage frequency. Although it provided useful insights, Lee et al. (2012) did have
several limitations. This study used a population of older adults in two US cities, Memphis, TN
and Pittsburgh, PA. It is possible that prescribing patterns, population demographics, and
population health may differ between these cities and other parts of the United States, limiting
generalizability of the results. Eligibility for this study was also restricted to individuals who

26

were free of functional limitations, including having the ability to walk without an assistive
device. These restrictions may have limited the representativeness of the study population and
may make it difficult to generalize the results to other older adults.
The other two studies, Wimmer et al. (2015) and Herson et al. (2015), were conducted to
investigate factors associated with regimen complexity in older adults. Both of these studies
occurred outside of the United States. Wimmer et al. used data from the Swedish National Study
of Aging and Care in Kungsholmen (SNAC-K), and Herson et al. used data from six long-term
care facilities in Southern Australia. These countries differ from the United States which may
limit the generalizability of their results to the United States. The results in Wimmer et al.
showed that participants with the most complex regimens had higher cognitive scores than
participants with less complex regimens. The authors noted that this was consistent with the
findings of Lee et al. and supported the idea that prescribers might have simplified medication
regimens to facilitate easier medication management in people with cognitive impairment.
However, Wimmer et al. mentioned that their results should be interpreted cautiously because
there was only a small variation in Mini Mental State Examination score across complexity
groups. Finally, Herson et al. (2015) focused on a population receiving assistance from nurses
and independent living facilities, which means that their results are unlikely to be applicable to
community-dwelling older adults who must manage their own medications.
Both Wimmer et al. and Herson et al. assessed the association between medication
regimen complexity and functional impairment (as measured using the index developed by Katz
et al.128). Wimmer et al. showed no association between functional impairment and medication
regimen and did not interpret this result further in their discussion. Herson et al. reported that
independence in ADLs was associated with lower medication regimen complexity, but also did
not interpret this result in their discussion, which suggests that they may interpret ADL
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impairment as being a manifestation of dementia. Herson et al. also stated that clinicians
discontinued or ‘deprescribed’ medications to residents with reduced life expectancy. The
inconsistent results for the relationship between functional impairment and medication regimen
complexity make it difficult to draw a clear conclusion from the existing literature. Additionally,
it would be desirable to investigate functional impairment using both ADLs and IADLs to obtain
more clear and precise data about functional ability. All of the studies included in this review are
cross sectional in design, which does not allow for the examination of changes over time. A
longitudinal study would be desirable to examine how cognitive and functional status is
associated with changes in medication regimen complexity over time. Additionally, no study has
investigated association between prescription medication regimen complexity and cognitive or
functional impairment in a nationally-representative dataset. This study will be the first study to
examine the relationship between cognitive/functional impairment and prescription regimen
complexity in older adults using a longitudinal design and nationally-representative data.
Conclusion
The review of the literature suggests that older adults with good cognition may have
higher medication regimen complexity than those with cognitive impairment. Two studies
provide two different results for the association between functional impairment in ADL and
medication regimen complexity, with one study reporting no significant association, and the
other reporting that independence in ADLs was inversely associated with high regimen
complexity. However, most of these studies used data from outside of the United States and had
other restrictions that may limit their generalizability. There is a need for further studies
investigating the association between cognitive/functional impairment and medication regimen
complexity, particularly studies using a longitudinal design and a nationally-representative
sample.
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Chapter 3: Methods

3.1 Data Source
This study used a nationally representative sample of individuals aged 65 and over, using
data from the Health and Retirement Study (HRS). HRS is nationally representative longitudinal
survey of more than 37,000 individuals over age 50 living in more than 23,000 households in the
United States. The HRS is supported by the National Institute on Aging and the Social Security
Administration. The survey began in 1992 and is conducted every two years, following the same
cohort of adults age 50 years or older, with new individuals added to the cohort at each wave.
The HRS collects data on physical and mental health, family support systems, financial status,
insurance coverage, and retirement planning. The HRS data is collected by interviewing the
participants either in person or via a telephone interview. For individuals who are unable to
complete the interview personally, a proxy completes the interview on their behalf. The main
HRS survey is a free and publicly available data set, while some specialized sub-components of
the survey are considered sensitive information and require a special approval to access
restricted-use data. This study used data from the HRS surveys administered in 2004 and 2006,
and also used data from the Prescription Drug Survey (PDS) sub-component of the HRS
administered only in 2005 and 2007. An additional follow-up was administered in 2009 (the
HRS 2009 Health and Well-Being Study), however the data release for the 2009 study did not
include the detailed descriptions of participants’ prescriptions, and therefore was not used for this
study.
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3.2 Study Design
This study used a retrospective cohort design, longitudinally following individuals over a
two-year period. Baseline data came from the 2004 HRS questionnaire and the 2005 PDS
questionnaire. Follow-up data came from the 2006 HRS questionnaire and the 2007 PDS
questionnaire. The data from these years was used to assess the association between medication
regimen complexity and cognitive/functional status at baseline and to assess the change in
medication regimen complexity over a two-year period.
3.3 Eligibility of Study Participants
This study included respondents who, at baseline in 2004, were age 65 years or older and
living in the community. In order to be eligible, participants must have been present in waves 7
(2004) and 8 (2006) of the HRS and must have completed the 2005 and 2007 PDS
questionnaires. Participants with missing data for the outcome variable (medication regimen
complexity) or the main predictors (functional or cognitive status) were excluded. In addition,
participants who lived in a nursing home at baseline or who were interviewed by proxy at
baseline were excluded. Thus, the study sample is representative of community-dwelling older
adults aged 65 years or older.
3.4 Outcome Variable
The outcome under study was medication regimen complexity, which was assessed
using a modified version of the medication regimen complexity index (mMRCI). the modified
version of the tool was done and was administered by Lee et al.35 The original MRCI is a
validated tool developed by George et al. (2004). The MRCI has strong inter-rater and test-retest
reliability.38 The MRCI is a 65-item tool designed to quantify three components of medication
regimen complexity. MRCI component "A" scores dosage form (e.g. tablets, injections, nasal
spray) as a contributor to complexity, component "B" scores dosage frequencies (e.g. once a day,
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every 12 hours) as a contributor to complexity and component "C" scores additional instructions
(e.g. “break the tablet in half” or “take with food”) as a measure of complexity. Each dosage
form is counted only once within a regimen. For example, if a patient's regimen consists of four
tablets that are taken orally, their MRCI component “A” sub-score would be one. The MRCI
component "B" measures dosing frequency (e.g. once a day, every 12 hours, alternate days) for
each medication. A weight is given to each medication frequency, with higher weights assigned
to greater frequencies. For example, if a patient is taking six medications with a frequency of
once a day for each medication, the MRCI component B sub score would be six. MRCI
component “C” measures additional directions (e.g. crush pill, take with food, taper dose). A
weight is given for each instruction per medication. For example, if a patient is on a single
medication that needs to be crushed and taken with meals, the component C score for that
medication is two. The Medication Regimen Complexity Index is a summary score of all three
components.
There is no limitation to the number of medications or special directions that may be
counted for a patient, and as a result the MRCI is an open index without an upper limit to the
possible range of scores.38 For the purpose of this study, a modified version of the medication
regimen complexity was created to account for the lack of information about additional
instructions in the HRS 2007 Prescription Drug Study. For consistency, the same modified scale
was applied to the 2005 data. The modified MRCI (mMRCI) score was calculated using the
dosage forms and dosage frequencies with the same weightings applied as in the MRCI except in
the scoring for frequencies in 2005, were coded as time per day not time per hrs. (for example: in
2005 some phrases like “take one tablet every 12 hrs.” the frequency was giving a score of 2
instead of 2.5 to ensure consistency across years. Details regarding dosage forms/dosage
frequencies and their assigned weights are shown in the original MRCI tool that is attached in the
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appendix A. The modifications to the MRCI resulted in a lower complexity score than the full
MRCI score since points for additional instructions were not included. As with the MRCI, higher
mMRCI scores indicate greater medication regimen complexity. In the analysis, the mMRCI was
used as a continuous variable.
3.5 HRS Prescription Drug Study
HRS 2005 Prescription Drug Study
The HRS 2005 Prescription Drug Study is a supplemental study that was conducted in
2005. It is the first wave of a two-wave mail survey designed to track changes in prescription
drug utilization. The PDS was intended to capture changes in prescription drug use associated
with the implementation of Medicare Part D in 2006, with the 2005 wave recording data prior to
the implementation of this program. The sample for the Prescription Drug Study (PDS) was
drawn from respondents to the main HRS survey in 2004. This questionnaire also included a
section containing detailed medication data, including drug names and information on dosage.
HRS 2007 Prescription Drug Survey
The HRS 2007 Prescription Drug Study (PDS) is the second wave of the PDS, conducted
in 2007 after the rollout of Medicare part D. The second wave was designed to capture similar
information to the first wave, but post-implementation. The sample for the 2007 wave of the
PDS consisted of everyone from the original 2005 sample who responded to either the PDS 2005
or to the HRS interview in 2006.

3.6 Drug information in HRS 2005 and 2007 Prescription Drug Study
The survey used in the 2005 Prescription Drug Study asked the participants to provide
information about each of the different medications they were taking and asked them to list all of
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their prescribed medications. Space was provided in Section E to list up to ten prescription
medications. Participants taking more than ten medications were asked to provide detailed
information about the ten medications they considered to be the most important, and then to list
all remaining medications in Section F. In section E, participants were asked to provide
information from the label on the prescription bottle such as the name and dose of the medication
(e.g. “Phenytoin (Dilantin) 100 mg”) and dosage instructions such as “Take one capsule by
mouth as directed in the morning and at bedtime.” Section F asked for drug names only and did
not include any other details.
The same instructions were used to collect prescription medication data in the 2007
Prescription Drug Study. However, in the 2007 survey, medication details in section E were
provided in a different format. The 2007 version of section E contained separate fields for
medication name (generic and brand name), medication strength (mgs or other units), format/unit
(e.g. capsule, tablet, inhalant, liquid, drop, other), and dosage frequency instructions (number of
units and number of times per day/week/month). Because the data fields provided about
medication regimen complexity components differed between the two years, data recoding was
necessary. The steps involved in the recoding process are shown in Table 3.1 below.
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Table 3. 1 Summery of the Steps Involved in the Recoding Process of the mMRCI
Steps
1. (In 2005) All medication instructions, such as “Take one capsule by mouth in the morning and at
bedtime” and were extracted and exported to an Excel spreadsheet to be manually interpreted and coded
in a manner consistent with the 2007 drug variables.
Details:
 Scoring was based on the original MRCI as described in Appendix A, except where specified
below
 Dosage frequencies given in hours, such as “every 12 hours” or “every 6 hours” were converted
to number of times per day and scored accordingly. (This differs from the original MRCI, in
which “every 12 hours” was scored as 2.5, but “twice per day” was scored as 2.)
 If prescription instructions were provided in a foreign language, they were translated using
Google Translate and then coded
 In instructions where multiple dosage frequencies were provided (such as “3-4 times per day”)
the more conservative (lower) score was assigned
 Drugs for which a dosage frequency could not be reliably determined but where a dosage form
was included were retained in the MRCI calculation.
2. (In 2007) All medication instructions such as (inhalant, drop, other) were extracted and exported to
an Excel spreadsheet to be manually interpreted and coded. Lexicomp® and drugs.com were used to
check the applicable sub format based on format, brand name, generic name and the strength of the drug
e.g. “1 drop daily” the brand name, generic name and the strength of the drug would be used to
check the Lexicomp® and drugs.com databases to determine whether the medication was
eardrops or eyedrops.

3. (Both years 2005 and 2007)
 For drugs with ambiguous dosage forms where the Lexicomp® or drugs.com databases found
multiple plausible matches, and the forms of the plausible matches would have different MRCI
scores, the form with the lowest MRCI score was used.
e.g. for a drug such as insulin, which can be available as a vial (score=4) or a prefilled
syringe (score=3) with identical strength and brand name, the lower score (3) was used
to calculate the MRCI
 Drugs for which a dosage form could not be reliably determined but where a frequency was
included were retained in the MRCI calculation.
 Drugs for which no information on dosage form and no information on frequency were
available, were excluded from the MRCI calculation.
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3.7 Creating the Complexity Variable and the Total Number of Medications
Scoring Procedure for the mMRCI
The mMRCI was computed by adding the summary scores for dosage form and
frequency from all of an individual’s prescriptions. Prescriptions with partial information (e.g.
missing form but known frequency, or missing frequency but known form) had all available
information counted towards the score. Prescriptions for which both form and frequency were
missing were considered invalid and did not contribute to an individual’s mMRCI score.
Individuals for whom all listed prescriptions were invalid were excluded. Some individuals in
2007 were found to have reported implausible values for drug frequency, such as reporting that a
prescription was taken 90 times per day. These individuals after applying the inclusion and
exclusion were 26 participants and were excluded from the study.
Creating the Total Number of Medications
The variable for number of medications was created based on the number of prescriptions
participants reported in section E. Because section E allowed for a maximum of 10 prescriptions,
this created a maximum value of 10 for this variable. Although participants were able to report
additional drugs in section F, section F did not provide details about drug frequency and format,
so these drugs could not be counted towards a participants mMRCI score. The PDS
questionnaire also included a question about how many drugs a participant took regularly, where
participants were able to provide a numeric answer with no upper limit, however, because dosage
form and frequency information for any drugs not reported in section E would not be available,
this variable was not suited for use in the present study. Total number of drugs was created by
taking the number of prescription medications reported by each individual in section E and
subtracting the number of medications for which both the frequency and the format were
missing, so that drugs that provided no information towards the mMRCI score would be
excluded.
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Individuals who had no prescriptions reported in section E, but who had answered “yes”
to earlier questions about medication use in section A were given a missing sample weight by the
PDS. All individuals with a missing PDS weight were excluded. Individuals who did not
complete section E but who had earlier reported that they were not using medications had
positive sample weights and were not excluded and were assigned a complexity of 0. After
scoring, the 2005 and 2007 data prescription drug surveys were merged. The two merged years
of the PDS were then merged with the HRS RAND data.
3.8 Predictor Variables
The main predictors under study were cognitive status and functional status.
Cognitive Status
Cognitive status as measured using the total cognition score from the HRS data. This
score was calculated as a sum of several tests comprising the Telephone Interview for Cognitive
Status (TICS) battery.129 The highest possible score was 35 points, with lower scores indicating
poorer cognitive function. Tests in the battery included total recall, a test of working memory,
and the mental status test. Total recall consisted of immediate free-recall (ability to remember a
list of 10 nouns the respondent has just heard) and delayed word recall (ability to remember the
same words after 5 minutes). The test of working memory was the serial 7s test, which asked the
participant to subtract 7 from 100, and to continue subtracting 7 from each subsequent number
for a total of five trials. The test of mental status included backward counting from 20 to 10, date
naming where respondents were asked to report “today’s date”, object naming where respondent
asked “What do you usually use to cut paper?” and “What do you call the kind of prickly plant
that grows in the desert?” and president/vice president naming where respondents were asked to
name the current president and vice president of the United States.
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Cognitive score was used as a continuous variable when modeling relationships with
overall complexity (at baseline, at follow-up, and longitudinally). For models examining subcomponents of complexity, cognitive impairment was dichotomized using cutoffs identified in
previous research using the HRS, with scores of 11 to 35 classified as “normal cognitive
function” and scores of 10 or lower classified as “cognitive impairment”. 130’131
Functional Status
Functional status was measured using Activities of Daily Living (ADLs)128, which are the basic
activities performed at home, and Instrumental Activities of Daily Living (IADLs)132, which are
the activities required for living independently in the community. The ADLs scale included
questions assessing the difficulty respondents experienced in walking across a room, dressing,
bathing, eating, and transferring (getting in and out of bed). The IADL scale included questions
assessing the difficulty respondents experienced when using the telephone, shopping, preparing
food, taking medication, and handling finances. Each score (ADL and IADL) ranged from 0-5,
with a higher score indicating that a respondent was able to perform a larger number of activities
without impairment. The scores were summary variables constructed as counts of the number of
ADL or IADL activities with which individuals reported at least “some difficulty”, so an
individual with a score of 0 reported impairments in 0 activities, while an individual with a score
of 5 reported impairments in all 5 activities.
Both scores were used as continuous variables when modeling relationships with overall
complexity (at baseline, at follow-up, and longitudinally). For models examining subcomponents of complexity, each score was dichotomized into categories of “no impairment” and
“one or more impairments”.
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3.9 Covariates
Socio-demographic covariates included age, gender, marital status, income (annual
household income in dollars), years of education (0 to 17+), race, perceived health status, history
of hospital stay in the previous two years, health insurance coverage, Medicare part D status,
depression, number of people in the household, and number of chronic conditions.
Demographic Data Variables
Older adults were categorized into three age groups (in years): 65-74, 75-84, and 85 and
above. Gender was categorized as male or female. Race was categorized as white, black, or
other. Marital status was categorized as married or non-married (non-married includes never
married, divorced, separated, and widowed). Annual income was grouped into five categories
based on rounded cutoffs for the 25th, 50th, 75th, and 95th percentiles. This resulted in categories
of $0-$15,999, $16,000-$28,999, $29,000-$50,999, $51,000-$134,999 and over $135,000. Years
of education was classified as “no degree”, “high school”, “some college”, and “college degree”.
Number of individuals in the household included the respondent, and was grouped into
categories of 1, 2-3, 4 or more.
Access to Health Care Variables
Insurance coverage status was treated as a dichotomous variable based on whether the
participant had any form of coverage (covered by federal government health insurance program,
covered by health insurance from a current or previous employer, covered by other health
insurance) or no coverage. Medicare Part D prescription coverage was introduced between the
2005 and 2007 waves, and thus was included only in follow-up and longitudinal models, but not
in the baseline models. In models that included Medicare Part D, it was treated as a type of
insurance coverage and incorporated into the dichotomous insurance coverage variable. History

38

of hospital stays in the previous 2 years was treated as a dichotomous variable coded as yes or
no.
Health Status Variables
The health status variable was obtained from the survey question asking participants to
self-rate their current general health condition. Excellent, very good and good were grouped
together and the variable was categorized as (excellent/very good/good, fair, or poor). Number of
chronic conditions was based on the number of questions to which participants had answered yes
when asked “Has a doctor ever told you that you have [condition]?” Conditions included in the
questionnaire were 1) high blood pressure or hypertension 2) diabetes or high blood sugar 3)
cancer or a malignant tumor of any kind except skin cancer 4) chronic lung disease such as
chronic bronchitis or emphysema 5) heart attack, coronary heart disease, angina, congestive heart
failure, or other heart problems 6) stroke or transient ischemic attack 7) emotional, nervous, or
psychiatric problems and 8) arthritis or rheumatism. The number of chronic conditions variable
was then categorized into none, 1-2, 3-4, and 5 or more. Depression was measured using a
continuous score derived from the Center for Epidemiologic Studies Depression (CES-D) scale
and was dichotomized into depression or no depression.
3.10 Missing Data
Following the initial application of inclusion and exclusion criteria, individuals were
checked for missing or invalid data. 11% of individuals who had met the initial criteria were
excluded for missing or invalid data on one or more variables. 2% of individuals had only invalid
prescriptions (prescription for which no frequency or format data was available). A further 8% of
individuals had not completed the prescription inventory despite answering “yes” to one or more
questions about taking medication. 1% of participants were excluded for reporting implausibly
high dosage frequency in 2007. For all other variables, including the main exposures (cognitive
39

and functional impairment) less than 5% of participants had missing data. Complete case
deletion was used to address the problem of missing data. To ensure that this deletion did not
create selection bias, individuals who were excluded for reasons related to the prescription
inventory (missing prescription inventory, invalid entries, or implausible dosage frequencies)
were compared to the rest of the sample on all major covariates using chi-square tests or Fisher
exact tests (depending on cell size). Individuals who were missing data on complexity were
significantly more likely to be unmarried, have a low income, more likely to have less than a
high school education, and more likely to be African American.
3.11 Statistical Analyses
Descriptive statistics were used to describe the baseline characteristics of our sample.
Continuous variables were expressed as the weighted mean ± standard deviation (SD).
Categorical variables were expressed as the unweighted frequency and weighted percent. For
both continuous and categorical variables, results were weighted to account for complex sample
design. To ensure comparability to the general HRS population, including in more recent years,
descriptive statistics were repeated using all participants in the 2012 wave of the HRS. The
results of this 2012 descriptive analysis can be found in Appendix B.
The predictors were then examined for compatibility with the assumptions of the linear
regression model. For continuous predictors, linearity of association with the outcome, normality
of residuals, and homoscedasticity of residuals were checked. The residuals were not normally
distributed, so the outcome variable complexity was log transformed, after which the regression
assumptions were met. Residuals were also examined to detect extreme outliers. For categorical
predictors, equal variance of residuals across categories was checked. All analyses were
conducted using survey procedures to account for complex sample design. Because it is possible

40

that the structure or composition of the PDS sample may have differed from that of the broader
HRS sample, weights specific to the PDS sample were used instead of the original HRS weights.
For aim I, characterization of medication regimen complexity among community
dwelling older adults, distributions of each complexity sub-component were checked for
normality. Because non-normal distributions were detected, the median and inter-quartiles ranges
were used to summarize the total mMRCI score and each portion of the mMRCI calculation
(number of medications, dosage form and dosage frequency). Dosage form and frequency were
treated as categorical variables and were summarized by reporting the most prevalent dosage
form and the most frequently observed dosage frequency among the population.
For the analysis for aims II and III, sub-aims 1, 2 (assessing the association between
medication regimen complexity and cognitive and functional status), survey-weighted
multivariable linear regression was used to examine the cross-sectional association between
mMRCI and each exposure (cognitive status and ADL status, and IADL status). For the
association between mMRCI score and cognitive status, multivariable linear regression models
were performed cross-sectionally at baseline and at follow-up. Similar analyses were applied to
assess the association between mMRCI score and functional status, with initial models assessing
cross-sectional associations. ADLs and IADLs were assessed separately. The assumptions of the
linear regression model were assessed. The residuals of the bivariate analysis between each subscore for dosage form or dosage frequency and the main predictors were not normally distributed
therefore log transformation was applied for the outcome. Finally, the “difficulty taking
medication” IADL was examined separately in association with complexity in both years. The
association between mMRCI score and both cognitive and functional impairment at baseline and
after two years was also examined. Due to low sample sizes in both groups, the analyses could
not be performed.
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For the analysis for aim II.3 and III.3 (“Compare factors that contribute to medication
regimen complexity in participants with and without cognitive impairment at baseline”) surveyweighted linear regression was used to compare each individual element of the mMRCI between
individuals with and without cognitive/functional impairments at baseline and after two years.
The assumptions of the linear regression model were assessed. The residuals of the bivariate
analysis between each sub-score for dosage form or dosage frequency and the main predictors
were not normally distributed therefore log transformation was applied for the outcome.
For II.4 and III.4, survey-weighted multivariable linear regression was used to examine
the change in mMRCI (2007 score - 2005 score) and its association with the change in cognitive
status at baseline as well as its association with the change in functional status (ADL score, and
IADL score separately). The assumptions of the linear regression model were assessed. Although
the residuals in the bivariate analysis were normally distributed, there residual vs. predictor plot
indicated heteroscedasticity, so the main predictors were categorized.
Change in yes/no covariates such as insurance coverage and history hospital stay were
assessed by taking the 2007 value and subtracting the 2005 value. The result from the subtraction
is (0, -1, and 1) which can then be used as a categorical variable. For the predictors ADLs,
IADLs and cognitive status, changes were created by subtracting across the years, then coding
the subtracted values into categories (0 = no change, < 0 = score decreased, > 0 = score
increased). Changes in ordinal variables such as self-rated health were also categorized into no
change, increase, and decrease. Other continuous variables (income, number of individuals in the
household, and number of health conditions) were categorized by change status. Change in
marital status was detected using subtraction, with a value of 0 indicating no change and values
above or below 0 indicating a change.
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Other covariates that were unlikely to change over the follow-up period such as gender and years
of education were represented by using the baseline variable. Additionally, because all
participants are expected to experience the same increase in age over the two-year follow-up
period, the baseline variable for age was used.
1. Sensitivity analyses were performed to determine how the interview types (face to face vs
telephone) would affect the results. Sensitivity analysis was done by performing the main
analysis between cognition status and medication complexity at baseline and after two
years with and without adjusting for the interview type variable and the same was done
for functional status (ADL and IADL) with medication complexity at baseline and after
two years. The results showed that after factoring in the interview type, the beta estimates
of cognition, ADL, and IADL changed by less than 1%. This indicates that the interview
type has no confounding effect.
2. Sensitivity analysis was performed, on the same people at baseline and after two years,
by repeating the multivariable linear analysis of comparing complexity factors in
participants with and without cognitive/functional impairment (ADL, IADL). The
analysis was done on two groups and then on three groups (impaired at both timepoints,
no impairment at both timepoints, and change in impairment between timepoints) and
since the result produced similar results, it was decided to use only two groups for
simplicity.
3. A sensitivity analysis was performed using cognitive decline (defined as score below 20)
to contrast the result with the results when using cognitive impairment (defined as a score
below 11).
4. The 2-way interaction was to test if any disease condition changed the association of
mMRCI with cognitive/functional impairment. If no 2-way interactions were observed,
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this would suggest that the other disease conditions did not change the association
between mMRCI and cognitive or functional impairment. Interactions between cognition,
ADL and IADL impairments and each disease conditions (cancer, heart disease, lung
disease, arthritis, psyche, stroke, diabetes, hypertension and depression) were tested at
baseline and after two years in the multivariable analysis. No significant interactions
were detected for cognition and ADLs. However, significant interactions were found for
IADLs and depression, therefore, stratified analysis was performed for IADL analysis by
depression status.
5. Multicollinearity was examined among the continuous variables by checking the
Pearson’s correlation coefficient. Since a high level of correlation was found between
ADL score and IADL score (r = 0.5, p<0.001) the two variables were kept in separate
models, and neither variable was used as a covariate when examining the other. All
statistical analyses were conducted using the SAS statistical software version 9.4 and
using an alpha cutoff of 0.05.
3.12 Human Subject Protection and Data Privacy
The data from the main HRS survey is free and publicly available, however the
Prescription Drug Study (PDS) is considered sensitive data and requires completing the Sensitive
Data Access Use Agreement. The study also was reviewed and approved as exempt by the VCU
IRB.
3.13 Sample Size of the study
The starting sample size was 3412 participants. After applying eligibility criteria, 2433
members of the sample remained, and 979 participants were excluded. After excluding
individuals who were missing data, 294 individuals were removed, and 2139 participant were
remained. The exclusion of individuals in 2007 who were found to have reported implausible
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values for drug frequency, resulting in a final sample size of 2113 participant. The diagram in
figure 3.1 shows the details of this process.

45

Starting population of
3412 participants

Interviewed in nursing
home were removed (n=30)

3382 participants
remaining
Interviewed by proxy were
removed (n=249)
3133 participants
remaining

Under 65 years old were
removed (n=700)

2433 participants
remaining

Excluded for missing data
in main predictors at
baseline or after two years
(n=44)

2389 participants
remaining

Excluded for missing in
outcome at baseline or after
two years (n=49)
2340 participants
remaining

Excluded for missing
prescription inventory at
baseline or after two years
(n=201)

2139 participants
remaining

Excluded individuals in
2007 who were found to
have reported implausible
values for drug frequency
(n=26)

2113 participants
remaining

Figure 1.1 Flow Chart Representing Inclusion and Exclusion for the Final Sample
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Chapter 4: Results

4.1 Characteristics of the Study Sample
Of the 2113 eligible participants, 58.75% were between the ages of 65 and 74 years,
58.37% were female, 90.97% were white, 78.61% had a high school or more advanced level of
education, 60.70 % were married, and 57.32% earned more than $28,000 per year. A large
majority (99.37%) were covered by insurance, and 77.19% reported their health was “excellent”,
“very good” or “good”. Approximately 12.30 % of participants reported having difficulty in
performing at least one of the ADLs, and approximately 9.80% reported having difficulty in
performing at least one of the IADLs. Only 1.01% of the sample had cognitive impairment. In
the 2007 data, the sample was slightly older, and had slightly higher prevalence for cognitive and
functional impairments and chronic conditions. Demographic characteristics of the study sample
at baseline and follow-up are summarized in Table 4.1. The results are weighted to account for
the complex sample design.
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Table 4.1 Summarizes the Demographic Characteristics of the Study Sample
Variables
Total population n=2113

N, weighted frequency (%)
(2005)

N, weighted frequency (%)
(2007)

65–74 years
75–84 years
85 years or older

1302 (58.75)
671 (34.84)
140 (6.40)

1097 (45.75)
794 (41.84)
222 (12.40)

Gender
Male
Female

850 (41.62)
1263 (58.37)

850 (41.62)
1263 (58.37)

Marital status
married
non-married

1334 (60.70)
778 (39.29)

1261 (54.70)
852 (45.29)

Race
White
Black
Other

1822 (90.97)
229 (6.02)
62 (3.00)

1822 (90.97)
229 (6.02)
62 (3.00)

Years of education
No degree
High school
Some college
College degree

535 (21.37)
930 (43.90)
249 (12.95)
399 (21.76)

535 (21.37)
930 (43.90)
249 (12.95)
399 (21.76)

Income
$ 0 to 15999
$16000 to 28999
$ 29000 to 50999
$ 51000 to 134999
$ over 135000

500 (20.24)
512 (22.43)
547 (27.40)
445 (23.90)
109 (6.01)

483 (23.24)
511 (22.43)
567 (27.40)
457 (22.90)
95 (4.01)

Covered by insurance
No
Yes

18 (0.62)
2092 (99.37)

17 (0.75)
2094 (99.24)

Age
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Variables
Total population n=2113

N, weighted frequency (%)
(2005)

N, weighted frequency (%)
(2007)

Number of people living
at house
1
2-3
4 or more

563 (28.63)
1441 (67.20)
109 (4.16)

628 (33.63)
1372 (62.20)
113 (4.16)

Previous hospital stay
No
Yes

1492 (71.37)
618 (28.62)

1441 (67.63)
669 (32.36)

Health
Excellent/very good/good
Fair
Poor

1581 (77.19)
402 (17.59)
129 (5.20)

1525 (70.19)
439 (21.59)
144 (8.20)

ADL
None
Impaired

1836 (87.69)
277 (12.30)

1749 (81.03)
364 (18.96)

IADL
None
Impaired

1894 (90.19)
219 (9.80)

1834 (85.16)
279 (14.83)

Cognitive status
Cognitive intact
Impaired

2080 (98.98)
33 (1.01)

2040 (97.58)
46 (2.41)

Number of conditions
none
1-2
3-4
5 or more

241 (11.40)
1118 (53.35)
659 (30.88)
95 (4.35)

178 (8.40)
1061 (49.35)
747 (35.88)
127 (6.35)

Depression
No
Yes

1854 (88.80)
259 (11.19)

1828 (86.31)
285 (13.68)
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4.2 Characterize Medication Complexity among the Population
Table 4.2 shows the survey-weighted and unweighted median values and interquartile
ranges for total medication complexity and each of its subscores. The survey-weighted median will
be presented in the results. The prescription complexity score ranged from 0 to 35, with a median
of 5.24 and interquartile range (IQR) of 2.65 to 8.98 The number of medications ranged from 0 to
10 medications. The upper limit of 10 was created because the space provided for participants to
fill out section “E” in the survey was limited to only 10 medications. Additional medications could
be listed in a separate file but did not include details such as form and frequency, these
medications were not counted towards complexity. The median number of medications was 2.86
(IQR 1.29 to 5.02). The complexity subscore from dosage form ranged from 0 to 14 with a median
of 0.80 (IQR 0.33 to 1.75). Lastly, the complexity subscore from dosage frequency ranged from 0
to 27 with a median of 3.56 (IQR 1.49 to 6.78). All measurements showed small increases in 2007,
as shown in Table 4.3.
In Table 4.4, the most common dosage form among the participants was oral medication
(tables/capsule) with 91.68% of the population taking at least one tablet or capsule. The next most
common form was inhaled medication, used by 9.02% of the population, followed by other dosage
forms (ointment, cream, injection, etc.) used by 7.54%, and lastly drops (eyedrops or ear drops)
used by 5.63%. The most common dosage frequency among the population was once per day with
87.79% taking at least one medication on this schedule, followed by two times per day with
47.39% of the population, followed by three times with 10.36% and lastly four times a day with
9.47% of the population. The prevalence of most dosage frequencies and forms showed small
increases in 2007, as shown in Table 4.5.
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Table 4.2 Medication Complexity Sub-Component Scores (2005)
Variables

Score range

Weighted median

Un-weighted median

(IQR)

(IQR)

Medication complexity

0-35

5.24 (2.65 to 8.98)

6.00 (3.00 to 9.00)

Number of medications

0-10

2.86 (1.29 to 5.02)

3.00 (2.00 to 5.00)

Dosage form score

0-14

0.80 (0.33 to 1.75)

1.00 (1.00 to 2.00)

Dosage frequency score

0-27

3.56 (1.49 to 6.78)

4.00 (2.00 to 7.00)

Table 4.3 Medication Complexity Sub-Component Scores (2007)
Variables

Score range

Weighted median

Un-weighted median

(IQR)

(IQR)

Medication complexity

0-35

6.45 (3.39 to 10.61)

7.00 (4.00 to 11.00)

Number of medications

0-10

3.73 (1.97 to 6.13)

4.00 (2.00 to 6.00)

Dosage form score

0-18

1.10 (0.46 to 1.95)

2.00 (1.00 to 2.00)

Dosage frequency score

0-23

4.47 (1.97 to 7.88)

5.00 (2.00 to 8.00)

51

Table 4.4 Percent of People Having Each Dosage Form and Dosage Frequency in 2005
Dosage form

Weighted percentage

Tablet/ Capsule

91.68%

Inhalation

9.02%

Others

7.54%

Drops

5.63%

Dosage frequency

Weighted percentage

Once/day

87.79%

Twice/day

47.39%

Three/day

10.36%

Four or more/day

9.47%

Table 4.5 Percent of People Having Each Dosage Form and Dosage Frequency in 2007
Dosage form

Weighted percentage

Tablet/ Capsule

92.81%

Inhalation

10.69%

Others

9.14%

Drops

5.93%

Dosage frequency

Weighted percentage

Once/day

88.59%

Twice/day

46.61%

Three/day

13.42%

Four or more/day

9.43%
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4.3 The Association between Medication Complexity and Cognitive Status at Baseline and
after Two Years
The fully-adjusted model at baseline showed that after adjusting for all covariates, for
every one-unit increase in cognition score, the medication complexity score was 1.02 times higher
(p<0.0001). This was confirmed by repeating the model after two years: in the 2007 data, it was
found that after adjusting for all covariates, for every one-unit increase in cognition score,
complexity increased by a factor of 1.01 (p= 0.0392). (Table 4.6)

Table 4.6 Adjusted Association between Cognitive Status and Medication Complexity
Variables

ß Coefficient*

P-value

1.02

<0.0001

1.01

0.0392

At baseline
Cognitive status

After two years
Cognitive status

* Due to a violation of the linearity assumption for regression, tests were performed on a logtransformed version of the variable, but results have been exponentiated to return to original values
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4.4 Compare Factors that Contribute to Medication Complexity in Participants with and
without Cognitive Impairment at Baseline and after Two Years
Comparing the complexity factors in those with and without cognitive impairment (defined
as score below 11) at baseline indicated that there were no statistically significant differences in
the number of medications score, dosage form score, or dosage frequency score between the two
groups (p =0.5087), (p=0.9348), and (p=0.9691), respectively. The analysis was repeated after two
years, and again did not detect any significant differences in the number of medications
(p=0.4156), dosage form score (p=0.0512), or dosage frequency score (p=0.1687) between the two
groups. (Table 4.7)
A sensitivity analysis was performed using cognitive decline (defined as score below 20) to
contrast this with the results when using cognitive impairment (defined as a score below 11).
While 1.01% of the sample met the criteria for cognitive impairment, 20.12% of the sample met
the criteria for cognitive decline. Table 4.6 shows the results of the sensitivity analysis using the
exposure of cognitive decline. These results indicated that there were significant differences
between those with cognitive decline and good cognition in number of medications (β =0.90,
p=0.0037) and dosage frequency scores (β =0.86, p=0.0019) at baseline. After adjusting for all
covariates, individuals with cognitive decline had lower dosage frequency (β =0.92, p=0.0368) and
dosage form (β =0.91, p=0.0305), than those who had good cognition, and no significant
difference in the number of medications between the two groups after two years. (Table 4.8)
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Table 4.7 Comparison of Complexity Factors in Participants with and
without Cognitive Impairment
Variables at baseline

ß Coefficient*

p-value

0.94

0.5087

0.93

0.9348

0.99

0.9691

ß Coefficient*

p-value

0.95

0.4156

0.87

0.0512

0.86

0.1687

Number of medications
Cognitive impairment

Dosage form
Cognitive impairment

Dosage frequency
Cognitive impairment

Variables after two years
Number of medications
Cognitive impairment

Dosage form
Cognitive impairment

Dosage frequency
Cognitive impairment

* Tests were performed on a log-transformed version of the variable, but results have been
exponentiated to return to original values.
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Table 4.8 Comparison of Complexity Factors in Participants with and
without Cognitive Decline
Variables at baseline

ß Coefficient*

p-value

0.90

0.0037

0.95

0.1585

0.86

0.0019

ß Coefficient*

p-value

0.92

0.1902

0.91

0.0305

0.92

0.0368

Number of medications
Cognitive impairment

Dosage form
Cognitive impairment

Dosage frequency
Cognitive impairment

Variables after two years
Number of medications
Cognitive impairment

Dosage form
Cognitive impairment

Dosage frequency
Cognitive impairment

* Tests were performed on a log-transformed version of the variable, but results have been
exponentiated to return to original values.
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4.5 The Association between Medication Complexity and Functional (ADL and IADL) Status
at Baseline and after Two Years

ADL Impairments
At baseline, adjusted comparison of complexity score and ADL score showed that after adjusting
for all covariates, for one-unit increase in ADL score, medication complexity was 1.06 times
higher (p=0.0029). This association remained significant after two years (p=0.0243). (Table 4.9)

Table 4.9 Adjusted Association between ADL Functional Status
and Medication Complexity
Variables

ß Coefficient*

p-value

1.06

0.0029

1.04

0.0243

ADL at baseline
Functional status

ADL after two years
Functional status

* Tests were performed on a log-transformed version of the variable, but results have been
exponentiated to return to original values.
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IADL Impairments
At baseline, there was significant association between IADL score and medication complexity. For
one-unit increase in IADL score, complexity was 1.07 times higher (p=0.0130). This association
did not remain significant after two years (p=0.2412). (Table 4.10)
Interactions between number of IADL impairments and each disease participant have been tested
at baseline and after two years. Significant interactions were detected between depression and
IADL score at both baseline and follow-up. Due to this interaction, the analyses were repeated
using stratification by depression status. (Table 4.11)
For participants without depression, at baseline after adjusting for all covariates, for one-unit
increase in IADL score, medication complexity was 1.14 times higher (p=0.0001) and for
participants with depression, no significant association between IADL score and complexity score
was detected at baseline (p=0.4679). After two years, for participants without depression, after
adjusting for all covariates, for one-unit increase in IADL score, medication complexity was 1.05
times higher (p=0.0334) and for participants with depression, no significant association between
IADL score and complexity score was detected (p=0.4003). (Table 4.11).
The number of individual who reported having difficulty taking medication in the IADL
measure was 26. In addition to that, the number of individuals with both cognitive impairment and
ADL impairment (n = 8) and both cognitive impairment and IADL impairment (n = 12) were too
low to provide adequate power for statistical testing, so individuals with difficulty taking
medication and multiple categories of impairment could not be analyzed as a separate group.
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Table 4.10 Association between IADL Functional Status and Medication Complexity
Variables

ß Coefficient*

p-value

1.07

0.0130

1.02

0.2412

IADL (unstratified) analysis at baseline
Functional status

IADL (unstratified) analysis at after two years
Functional status

* Tests were performed on a log-transformed version of the variable, but results have been exponentiated
to return to original values

Table 4.11 Association between IADL Functional Status and Medication
Complexity, Stratified by Depression
Variables

Not depressed
ß Coefficient*

p-value

Depressed
ß Coefficient *

p-value

IADLs at baseline

1.14

0.0001

0.97

0.4679

IADLs after two years

1.05

0.0334

0.96

0.4003

* Tests were performed on a log-transformed version of the variable, but results have been exponentiated
to return to original values.
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4.6 Compare Factors that Contribute to Medication Complexity in Participants with and
without Functional Impairment (ADL and IADL) at Baseline and after Two Years
ADL Impairments

There was a significant difference in the number of medications and dosage frequency
between the ADL-impaired and the ADL-unimpaired groups. After adjusting for all covariates,
ADL functional impairment was associated with a higher number of medications (β =1.13,
p=<.0001) and a higher dosage frequency (β =1.14, p=0.0005) compared to those without ADL
impairment. There was no significant difference in the dosage form score between the two groups
at baseline (p=0.9174). These results were repeated after two years, and results showed the same.
After adjusting for all covariates, individual who have ADL impairment are associated with higher
number of medications and higher dosage frequency than those without ADL impairment (β =1.09,
p=0.0170), (β =1.07, p=0.0431) respectively. (Table 4.12)
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Table 4.12 Comparison of Complexity Factors in Participants with and without
Functional Impairment in ADLs
Variables at baseline

ß Coefficient*

p-value

1.13

<0.0001

1.00

0.9174

Number of medications
Functional impairment

Dosage form
Functional impairment

Dosage frequency
Functional impairment

Variables after two years

1.14

0.0005

ß Coefficient*

p-value

1.09

0.0170

1.02

0.3294

1.07

0.0431

Number of medications
Functional impairment

Dosage form
Functional impairment

Dosage frequency
Functional impairment

* Tests were performed on a log-transformed version of the variable, but results have been
exponentiated to return to original values.
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IADL Impairments
There was a significant difference in the number of medications and dosage frequency
between the IADL-impaired and IADL-unimpaired groups. After adjusting for all covariates,
IADL functional impairment was associated with higher number of medications (β =1.17,
p=0.0017) and a higher dosage frequency score (β =1.23, p=0.0002) compared to those without
IADL impairment. There was no significant difference in the dosage form score between the two
groups at baseline (p=0.1505). These results were repeated after two years, results showed that no
significant difference was found for number of medications, dosage form and dosage frequency
between the two groups (Table 4.13).
IADL Impairments Stratified by Depression
After adjusting for all covariates, individuals with IADL impairment and who were not
depressed had significantly higher numbers of medications than individuals without impairments
(β=1.24, p=0.0002). Individuals with IADL impairments also had significantly higher scores for
dosage frequency (β=1.32, p <.0001) and dosage form (β=1.12, p= 0.0366) at baseline. These
differences remained significant only for number of medications but not for dosage form and
dosage frequency after two years. Those with IADL impairment and not depressed had higher
number of medication (β =1.13, p=0.0426) than those without IADL impairment. Among
individuals with depression, those with and without IADL impairments did not differ in number of
medications, dosage form score, or dosage frequency score. This result was the same at baseline
and after two years. (Table 4.14).
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Table 4.13 Comparison of Complexity Factors in Participants with and without
Functional Impairment in IADLs
Variables at baseline

ß Coefficient*

p-value

1.17

0.0017

1.07

0.1505

Number of medications
Functional impairment

Dosage form
Functional impairment

Dosage frequency
Functional impairment

Variables after two years

1.23

0.0002

ß Coefficient*

p-value

1.03

0.4267

1.05

0.2146

1.04

0.3568

Number of medications
Functional impairment

Dosage form
Functional impairment

Dosage frequency
Functional impairment

* Tests were performed on a log-transformed version of the variable, but results have been exponentiated
to return to original values.
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Table 4.14 Comparison of Complexity Factors in Participants with and without
Functional Impairment in IADLs

Variables at baseline

Not depressed
ß Coefficient*

p-value

Depressed
ß Coefficient*

p-value

1.24

0.0002

1.00

0.9573

1.12

0.0366

0.96

0.6458

1.32

<.0001

1.01

0.9310

Not depressed
ß Coefficient*

p-value

Depressed
ß Coefficient*

p-value

1.13

0.0426

0.92

0.3277

1.06

0.2145

1.03

0.6464

1.10

0.0899

0.89

0.1806

Number of medications
Functional impairment
Dosage form
Functional impairment

Dosage frequency
Functional impairment

Variables after two years
Number of medications
Functional impairment

Dosage form
Functional impairment

Dosage frequency
Functional impairment

* Tests were performed on a log-transformed version of the variable, but results have been exponentiated
to return to original values.
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4.7 Assess the Change in Medication Regimen Complexity Score and its Association with
Change in Cognitive and Functional Status over Two Years
The analysis of the association between the change in mMRCI score and the change in each
of the main predictors (ADL status, IADL status, and cognitive status) showed that there were no
significant differences in the changes in mMRCI score after two years. (Table 4.15)

Table 4.15 Association Between Change in Predictors and Changes
in Medication Complexity
Variables

ß Coefficient

p-value

Ref

Ref

Cognitive declined

-0.19

0.5068

Cognitive improved

0.01

0.9956

No change

Ref

Ref

Functional declined

0.19

0.7579

Functional improved

0.24

0.6003

No change

Ref

Ref

Functional declined

0.67

0.3166

Functional improved

0.57

0.2614

Cognitive status
No change

Functional status (ADL)

Functional status (IADL)
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4.8 Summery
These results support the existence of a relationship between good cognition and
complexity, with cognitive impairment associated with lower medication regimen complexity. The
decreased complexity was primarily due to the less complicated dosage forms and dosage
frequencies prescribed to these individuals. ADL impairment shows more robust association with
the increasing of medication regimen complexity than IADL impairment. ADL impairment was
associated with higher medication regimen complexity at both baseline and after two years, with
the number of medications and dosage frequency showing similar increases. The association
between IADL and medication regimen complexity needs further investigation. Stratifying by
depression status, IADL impairment was found to predict higher complexity in participants
without depression but not participants with depression. There was no significant relationship
between changes in cognitive/functional status and changes in medication regimen complexity
over two years, however there is a need to continue to assess these changes over a longer period of
time.
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Chapter 5: Discussion

5.1 The Relationship between Cognitive Status and Medication Regimen Complexity
Higher cognitive scores were associated with higher medication regimen complexity, and
lower cognitive scores were associated with lower complexity. This association could be the result
of prescribers stopping or decreasing medications for cognitively impaired patients in
consideration of the disease trajectory, treatment care goals, and life expectancy of the patients.133
The observed decrease in medication complexity was present regardless of the type of chronic
disease affecting the patient. This might reflect a switch from potentially curative therapy intended
to prolong the patient’s life to palliative treatment intended to provide symptomatic relief while
reducing the adverse effects from medication.134 Furthermore, the deterioration of the cognitive
function might lead the physicians to reassess the patient’s medication regimen which leads to
reductions in medication regimen complexity.133 Patients or care providers may also request that
physicians prescribe a simpler regimen in response to subclinical or overt cognitive impairment.
This is consistent with a previous study by Lee et al. which reported that cognitive impairment was
inversely associated with medication regimen complexity and suggested that clinicians may have
made the regimens less complicated in order to make it more convenient for the patients to manage
their medications.35 This is also consistent with the results of Wimmer et al. who found that
patients with more complex regimens had higher cognitive scores than patients with less complex
regimens.36
The attributable reason of why cognitive impairment was associated with lower complexity
was further investigated. Using a cutoff score of 11 to define cognitive impairment135’131, the
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cognitively impaired group did have fewer medications and less complex dosage forms and dosage
frequencies, but these differences were not statistically significant. The results may not have
reached significance because only a very small proportion of the sample (1.01%) had a cognitive
score below the cutoff. Sensitivity analysis using a higher cutoff of 20 to represent cognitive
decline,136 resulted in 20.12% of the sample being classified as having lower cognitive
performance. With this definition, the results showed that at baseline those with cognitive decline
had significantly lower number of medication and less dosage frequencies.
After two years still, those with cognitive decline had less dosage frequencies in addition to
less complex dosage forms. However, number of medication no longer become significant with the
higher cognitive score cutoff; there were no differences in the number of medications between the
cognitive decline and normal cognitive function groups after two years. This is consistent with the
results of Lee et al. who found no difference in number of medications between groups, and who
suggested that the differences in complexity could result from other factors such as form and
frequency.35
5.2 The Relationship between Functional Status and Medication Regimen Complexity
Higher ADL scores (which indicate greater functional impairment) were associated with higher
medication regimen complexity at baseline and after two years. This was consistent with the
results of Herson et al.34 who found that independence in activities of daily living (ADLs) was
associated with low regimen complexity. Our results indicated that the higher medication regimen
complexity in the functionally impaired group was attributable to significantly higher numbers of
prescriptions, as well as higher dosage frequencies. Many chronic conditions require treatment,
thus multiple comorbidities are associated with higher medication regimen complexity.36
Depending on the severity of the conditions, patients may have increased number of medications,
dosage forms, and frequencies of intake. Chronic conditions may also lead to difficulties in
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walking, standing, and fine motor skills, contributing to functional impairment.137 However, no
interactions were found between functional impairment and specific chronic conditions, indicating
that functional impairment was associated with increased complexity regardless of which specific
chronic conditions were present.
The findings from this study show that ADL functional impairment scores can serve as a
predictor of medication regimen complexity, which suggests that there are opportunities for health
care providers to intervene by re-assessing medication regimens for functionally impaired patients.
Complex medication regimes have been linked with poor adherence.25‘27 Functional impairment is
also known to reduce compliance with medication regimens.105’106 These results indicate that more
effort is required to reduce medication regimen complexity in geriatric patients with impaired
ADLs.
Although there was an association between ADL impairment and complexity, there was no
clear association between IADL impairment and medication complexity. The association was
significant at baseline but not after two years. Therefore, this association requires further
investigation. One way to interpret the results would be to look at the relationship between IADL
and cognitive impairment. The high correlation between cognitive decline and a decline in the
ability to perform IADLs has been shown in previous studies.138’139 IADLs require more complex
neuropsychological processing capacity than ADLs and therefore are more prone to deterioration
triggered by cognitive decline.140’141 In particular, a decline in executive function can be a key
contributor to impairment in IADLs.138 Functional deficits have been observed early in the course
of cognitive decline.142’143 Nygård et al. reported that IADLs can be impaired before the onset of
dementia, and should therefore be included in the diagnosis of mild cognitive impairment.144
Therefore, we could assume that doctors tend to reduce the medication complexity for their
patients based on their cognitive function. Meanwhile, the functional status of the patients is often
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not investigated as much. Establishing a baseline of cognitive function and functional status is not
the current standard of practice. The functional and cognitive status of patients has been shown to
correlate well with multiple outcomes such as their length of hospitalization, recovery and their
ability to carry out their activities post recovery. In order to have better data to assess the
relationship between functional status IADLs and medication regimen complexity, we must
promote their assessment as the standard of care in various medical settings.145
When stratifying by depression status, the result showed that IADL impairment was
significantly associated with higher medication regimen complexity only in the strata of
individuals without depression, and that there was no significant association between IADL
impairment and medication regimen complexity for individuals with depression. The lack of a
significant result in the depression strata could have been due to the relatively small sample size of
this strata (259 people) which may have reduced statistical power, however the interaction term
between IADL impairment and depression status was significant in the unstratified model which
suggests that there may be a true underlying difference.
Although depression treatment may lead to increases in medication regimen complexity35,
individuals with depression often do not seek help or receive treatment. Individuals with
depression are also more likely to neglect their health, less likely to seek medical advice, and more
likely to forget to take their medications or even pick them up.146 Depression may be a barrier to
adherence with a complicated medication regimen, with patients who are depressed being less
likely to take their medications as prescribed.147 It has been reported that there is a threefold
increase in the odds of non-compliance among individuals with depression.148 As such, this lack of
significance could be explained by the fact that even if these individuals should have had a high
number of medications, they may not have sought help or been compliant with their medication
regimens, leading to lower medication use and therefore lower reported complexity.

70

5.3 The Relationship between Changes in Cognitive/Functional Status and Changes in the
Medication Regimen Complexity
There were no significant associations between changes in cognitive impairment, ADL
impairment, or IADL impairment and changes in complexity over two years. In an aging
population, there are some characteristics like cognition, functional ability, and medication
complexity that are expected to change over time. Cognition and function will likely decline, due
in part to the natural process of aging.149 Similarly, as older adults age they face more health
issues, that often require them to take multiple medications to treat chronic health problems and,
based on that, the nature of medication complexity will also change becoming more
complex.10’11’12 These changes may take years to manifest, and the ages at which they occur may
differ between individuals based on genetics, lifestyle, and prior medical history.150 Rates of
decline may become more rapid in the later stages of disease, which may not be captured with only
two years of follow-up.151 Another important factor to consider is hospitalization, which is
associated with greater changes in cognitive and functional impairment and with increases in
complexity.152 Only 28.6% of our sample reported hospitalization during the two years of follow
up, which may have limited our ability to detect hospitalization-related changes.
Descriptive analysis found that the majority of the sample (58.75%) was in the youngest
age group of 65-74 years old. Most of the sample (98.98%) had good cognition, and the prevalence
of ADL impairments and IADL impairments was low (12.30% and 9.80% respectively). 77.19%
of participants reported that their health was excellent, very good, or good. The prevalence of most
chronic conditions was low, with the exceptions of hypertension (66.52%) and arthritis (62.83%).
These results indicate that participants in the Prescription Drug Study were a fairly healthy sample.
The prevalence of most chronic conditions, and the prevalence of ADL and IADL impairments,
did not differ between the PDS sample and the overall HRS sample.
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For comparison, the sample used in this study was compared to a more recent HRS sample
from 2012. Similar to the PDS, the majority of the HRS 2012 participants (57.12%) were in the
youngest age group (65 to 74 years old). The majority of the sample had good cognition (96.55%),
15.02% reported IADL impairments, and 16.84% reported ADL impairment. As in the PDS
sample, the prevalence of most of the chronic conditions was low, with the exceptions of
hypertension (68.34%) and arthritis (68.94%). 73.13% of participants reported that their health was
excellent, very good, or good. Details of the 2012 comparison sample can be found in appendix B.
Over the two years of follow-up, the PDS sample did not experience large changes in the
prevalence of cognitive impairment (1.01% vs. 2.41%), IADL impairment (9.80% vs. 14.83%), or
ADL impairment (12.30% vs. 18.90%). This may also help to explain why no significant
relationship was detected between changes in these predictors and changes in complexity between
the two periods.
5.4 Strengths and Limitations
Results should be interpreted in light of the strengths and limitations of this study.
Although the data was longitudinal, only two years of follow-up were available in the PDS, so any
changes occurring beyond these two years were not captured. Although a longer follow-up period
would be desirable this data is not currently available. PDS data was not captured at the same time
as the primary HRS survey data, thus it is possible that undetected changes between times of
measurement may influence results (for example, an individual with low impairment in the 2004
HRS survey may have suffered a stroke and experienced increased impairment before the 2005
PDS survey). Because the HRS used both telephone and face-to-face interview modes, and only a
subset of cognitive tests could be performed during the telephone interviews, it was not possible to
measure all aspects of cognitive function such as executive function.
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As with all survey data, bias affecting self-reported answers cannot be eliminated. The
medication inventory is completed by the participants as part of a mail-in survey or telephone
interview. Cognitive impairment may have impacted the reporting of medication because people
with cognitive impairment may be less able to provide accurate medication information, creating
recall bias. It was possible to check for certain types of missing information. The impaired and
unimpaired groups did not show large differences in the percent of individuals leaving the
prescription inventory section blank (5.7% and 6.4%, respectively). The percent of individuals
who omitted frequency or format details for at least one prescriptions also did not show large
differences (29.8% in those without cognitive impairment, and 28.7% in those with cognitive
impairment). Other missing information could not be checked, such as individuals leaving
prescriptions out of the inventory or providing inaccurate details, so it is still possible that this
could have contributed to bias. The measures used in HRS to assess functional status are also
based on self-report of participants’ functional status at the time of interview and may not capture
fluctuations in functional status over time unless they are substantial.
Although the PDS survey asked participants to report their over the counter medications in
a separate section, this section did not include any details about dosage form and dosage
frequency, so only prescription medications were considered when calculating the complexity
score. Individuals with partially missing prescription details were included in the study, which
likely led to lower complexity scores for these participants as the missing data could not count
towards their complexity scores. Although the low scores for these individuals are not ideal,
including these individuals in the sample was still preferable, because omitting them would have
excluded a large proportion of the sample and would also have led to biased and nonrepresentative sample. The detailed drug report section allowed a maximum of 10 prescriptions, so
individuals with more than 10 prescriptions could not report all their medications and would also
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have received lower complexity scores. Of the 2113 participants, only 54 people (2.6%) at baseline
and 83 people (3.9%) at follow-up responded to the question “How many medications do you take
regularly?” with a number greater than 10. This means that most of the sample would have been
able to report all of their medications in the prescription inventory, which reduces the potential
impact of this limitation. Finally, because the PDS data lacked information about additional
directions included with the prescription, the complexity measurement instrument used in this
study was a modified scale that did not account for this dimension of complexity, leading to a
lower total complexity score. Although this reduces comparability with other studies that used the
full instrument, the modified instrument has also been used in other studies, so it is possible to
compare the results of this study with some existing literature. (cite) Additionally, existing
literature using the full complexity instrument has reported that form and frequency are the two
components with the greatest effect on complexity, and these two factors are included in the
modified instrument.
It was not possible to perform analysis of individuals with both functional and cognitive
impairment due to small sample sizes (8 people had both cognitive and ADL impairments, and 12
people had both cognitive and IADL impairments). The criteria excluding those interviewed by
proxy at baseline (7.3% of the population) is likely to have led to underrepresentation of those with
the most severe cognitive or functional impairments and may also have led to underrepresentation
of individuals with both cognitive and functional impairment. However, the purpose of this study
was to examine complexity among people who were able to care for themselves and were likely to
be managing their own medications, and such individuals would be unlikely to be interviewed by
proxy, so the exclusion criteria were consistent with the study intentions. However, future studies
examining complexity in more severely impaired individuals are recommended.
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Due to the data usage agreement with the HRS, it was not possible to share the prescription
details with others. With only one person coding the prescriptions, it was not possible to test interrater reliability. However, the differences between prescription complexity in 2005 (where
prescription details were coded by hand) and 2007 (where the majority of prescription details were
coded by HRS staff) were not large and were in the expected direction (as study participants got
older, their complexity was expected to increase) which suggests that the hand-coded details were
fairly consistent with the HRS-coded details.
The PDS data was collected in 2005 and 2007, and it is possible that there may have been
some changes in clinical and prescribing practices since then. However, recent literature suggests
that the need to assess for cognitive and functional impairments in clinical settings is still an
important issue, which would suggest that practitioners are still often not accounting for these
factors. Thus, although this study uses older data, it still contributes important information to
support the need for prescribers to assess impairment and review medication complexity to
improve adherence in older adults.
This study also had several strengths, including the use of a complexity score that reflected
multiple dimension of complexity (number of medications, dosage form, and dosage frequency),
the use of longitudinal data, and the availability of detailed covariates that allowed for thorough
assessment of confounding. This study also assessed ADL, IADL, and cognitive impairment in
tandem in the same sample, and was the first study to do so using longitudinal data from a
nationally-representative sample. Another strength of this study was that interactions were
examined between chronic conditions and each of the main predictors, which confirmed that the
associations between impairment and complexity were robust across a variety of conditions.
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5.5 Implications and Future Directions
The results of this study have three main implications for clinical practice. First, regular
assessment of cognitive and functional impairments should be a standard of care for older adults.
Second, it is important to review medications to identify complex regimens that increase risk of
poor adherence. Finally, it is important to combine this information to identify individuals with
impairments and complex medication regimens who may be particularly in need of interventions to
reduce their regimen complexity while still meeting their medical needs.
To facilitate these recommendations, it will be important to have an interconnected system
to manage information from all of a patient’s healthcare providers, so doctors can be aware of all
of their patients’ prescriptions from different sources and be able to account for this in their own
prescribing and to communicate any concerns to the patient’s other providers. Doctors should also
routinely assess for cognitive and functional impairment that may indicate a particularly strong
need to reduce a patient’s prescription complexity. Some programs, such as Medicare, have
implemented a requirement for assessment of cognitive impairment as part of an annual wellness
appointment, however more frequent assessments including both cognitive and functional
impairment should become a routine standard of care.
The findings of this study can play a significant role in encouraging further research in this
area. Although this is an observational study that cannot demonstrate causation, it does provide
evidence of an association between complexity and impairment. Existing studies have shown that
individuals with impairment are at higher risk poor adherence, and that higher complexity is also a
risk factor for poor adherence. Based on this information, it seems reasonable to suggest an
intervention study to assess whether reducing complexity for those with cognitive/functional
impairment would improve their adherence. The intervention study could also include individuals
without impairments, to see if the intervention has a greater impact for individuals with
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impairments, especially individuals with functional impairments who are likely to have higher
complexity. Also, more studies are needed to assess the association between cognitive/functional
impairment and medication complexity over longer periods of time, particularly to clarify the
relationship between IADL impairment and complexity. Further research is also needed to
investigate how changes in cognitive/functional status would predict changes in medication
complexity over longer periods of time. This would help determine how the changes in functional
status would predict the changes in MRCI. Also, it would be interesting to include all
prescriptions and over the counter medications in the study to determine which has the greatest
effect on complexity. We were not able to determine this in our study because of the nature of
HRS data that only captures full details for prescription medication.
5.6 Conclusion
This population-based retrospective longitudinal study was conducted to understand the
cross-sectional associations between cognitive status, functional status and medication regimen
complexity among older adults, and to examine how changes in these factors would predict the
changes in medication regimen complexity over a period of two years. The analysis found that
ADL impairment was a key predictor of higher medication regimen complexity but IADL
impairment association with medication complexity needed further investigation. Cognitive
impairment was associated with lower medication regimen complexity. None of the changes in
these factors were predictors of change in medication regimen complexity over two years.
Suggestions for future research in this area include 1) investigating the relationship between IADL
impairment and medication regimen complexity among older adults, 2) studying the association
between the change in cognitive/functional status and the change in medication regimen
complexity over longer period of time, 3) studying the effect of medication regimen complexity
on adherence of those with and without cognitive/functional impairment and 4) whether functional
77

status assessment in clinical practice would result in reduced medication complexity and therefore
improved medication adherence.
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Appendix A

The Medication Regimen Complexity Index, Section A (George et al., 2004, p. 1374)
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The Medication Regimen Complexity Index, Sections B and C (George et al., 2004, p. 1375)
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Appendix B

Table 4.1 Summarizes the Demographic Characteristics of the Study Sample at 2012
Variables
Total population n= 9694

N, weighted frequency (%)

Age
65–74 years
75–84 years
85 years or older

4834 (57.06)
3724 (31.47)
1136 (11.46)

Gender
Male
Female

4026 (43.02)
5668 (56.97)

Marital status
married
non-married

5799 (58.81)
3893 (41.18)

Race
White
Black
Other

7977 (87.47)
1324 (8.58)
389 (3.94)

Years of education
No degree
High school
Some college
College degree

2189 (19.63)
4060 (41.52)
1353 (14.40)
2085 (24.43)

Income
$ 0 to 15999
$16000 to 28999
$ 29000 to 50999
$ 51000 to 134999
$ over 135000

1810 (17.26)
2051 (19.46)
2628 (26.31)
2584 (28.98)
621 (7.96)

Number of people living at house
1
2-3
4 or more

2747 (31.18)
6219 (62.11)
728 (6.69)

Covered by insurance
No
Yes

0 (0)
9512 (100)
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Previous hospital stay
No
Yes

6697 (70.02)
2943 (29.97)

Health
excellent/very good/good
fair
Poor

6917 (73.13)
2031 (19.78)
733 (7.07)

ADL
None
Impaired

7958 (83.15)
1728 (16.84)

IADL
None
Impaired

8129 (84.97)
1557 (15.02)

Difficulty taking medication
No
Yes

9271 (97.19)
291 (2.67)

Cognitive status
Cognitive intact
Impaired

9301 (96.55)
393 (3.44)

Cognitive and ADL
No
Yes

9538 (98.67)
156 (1.32)

Cognitive and IADL
No
Yes

9500 (98.25)
194 (1.74)

Number of conditions
none
1-2
3-4
5 or more

557 (6.56)
4294 (45.59)
3893 (38.60)
945 (9.23)

Hypertension
No
Yes

2798 (31.65)
6744 (68.34)

Heart disease
No
Yes

6509 (68.39)
3168 (31.60)
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Lung disease
No
Yes

8465 (87.70)
1215 (12.29)

Arthritis
No
Yes

2863 (31.05)
6817 (68.94)

Stroke
No
Yes

8598 (89.53)
1084 (10.46)

Depression
No
Yes

8418 (87.52)
1276 (12.47)

Cancer
No
Yes

7637 (79.36)
2023 (20.63)

Psyche
No
Yes

8061 (82.46)
1618 (17.53)

Diabetes
No
Yes

7345 (83.38)
1641 (16.61)
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